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ABSTRACT 
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of chronic 
muscle disorders, typically displaying infiltrating T cells in skeletal muscle tissue and 
classified into polymyositis, dermatomyositis and sporadic inclusion body myositis. 
Several studies involving both humans and animal models point towards a role for T 
cells in the pathogenesis of IIMs, however, the precise phenotype, functionality and 
specificity of pathogenic T cells remain elusive. Increased frequencies of a subset of T 
cells, known as CD28null T cells, in peripheral blood and affected organs in various 
chronic inflammatory disorders, are reported by several studies. Such CD28null T cells 
are highly differentiated T cells lacking the co-stimulatory molecule CD28, which 
acquire expression of other receptors commonly associated with natural killer cells, and 
display proinflammatory, cytotoxic and apoptosis resistant features. In contrast to 
CD28null T cells, regulatory T cells are T cell subset critical for maintaining immune 
tolerance and also described to assist in the muscle repair process. 
The aims of this thesis were to investigate CD28null T cell subsets in both muscle 
tissue and peripheral blood of patients with IIMs, by evaluating frequencies, phenotype, 
function and clinical relevance of these cells. The cytotoxic mechanisms of CD28null T 
cells towards autologous muscle cells were investigated using in vitro T cell - muscle 
cell co-cultures. Muscle tissues of patients were investigated for the effects of 
conventional immunosuppressive therapies on CD28null and regulatory T cell subsets. 
Glucocorticoid and regulatory T cells mediated immunosuppressive effects on 
circulating CD28nulls T cells were evaluated using in vitro assays.  
We demonstrate that muscle-infiltrating T cells are predominantly CD4+CD28null and 
CD8+CD28null T cells in patients with polymyositis and dermatomyositis. Also in 
sporadic inclusion body myositis, where the role of immune system is controversial, T 
cell infiltrates in muscle tissue are dominated by CD28null T cells. Circulating 
CD28null T cell subsets of both CD4 and CD8 lineage were more common in patients 
compared to healthy controls, and were associated with human cytomegalovirus 
infection. These cells displayed oligoclonal expansions, proinflammatory cytokine 
secretion and degranulation potential, and also contained perforin. Using autologous in 
vitro co-cultures, we showed that the cytotoxic effects of CD28null T cells towards 
muscle cells are mediated largely via perforin-dependent mechanisms and regulated by 
IFNγ-induced HLA expression on muscle cells. Interestingly, poor clinical response in 
patients following immunosuppressive therapy was linked to persistence of CD28null T 
cells in muscle tissue. CD4+CD28null T cells were also found to be resistant towards 
glucocorticoid and regulatory T cell mediated immunosuppression in in vitro assays. 
These findings imply that CD28null T cells represent clinically important effector cells 
in IIMs, capable of attacking muscle fibers and inducing chronic inflammation 
mediated pathogenesis. Ineffectiveness of current immunosuppressive therapies 
appears to be linked with persistent CD28null T cells in muscle tissue as well as their 
immunosuppression resistant properties; therefore, these cells represent potential target 
candidates for future therapies.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF SCIENTIFIC PAPERS  
I.  Andreas	   E.	   R.	   Fasth,	   Maryam	   Dastmalchi*,	   Afsar	   Rahbar*,	   Stina	   Salomonsson,	  
Jayesh	  M.	   	   Pandya,	   Eva	   Lindroos,	   Inger	   Nennesmo,	   Karl-­‐Johan	  Malmberg,	   Cecilia	  
Söderberg-­‐Nauclér,	  Christina	  Trollmo,	  Ingrid	  E.	  Lundberg	  and	  Vivianne	  Malmström.	  
T	  cell	  infiltrates	  in	  the	  muscles	  of	  patients	  with	  dermatomyositis	  and	  polymyositis	  
are	  dominated	  by	  CD28null	  T	  cells.	  
Journal	  of	  Immunology,	  2009,	  Oct	  1;183(7):4792-­‐9	  
	  
II.  Jayesh	  M.	  Pandya,	  Andreas	  E.	  R.	  Fasth,	  Mei	  Zong,	  Snjolaug	  Arnardottir,	   Lara	  Dani,	  
Eva	  Lindroos,	  Vivianne	  Malmström	  and	  Ingrid	  E.	  Lundberg.	  
Expanded	   TCR-­‐Vβ	   Restricted	   T	   cells	   from	   Sporadic	   Inclusion	   Body	   Myositis	  
Patients	  are	  Proinflammatory	  and	  Cytotoxic	  CD28null	  T	  cells.	  
Arthritis	  &	  Rheumatism.	  2010	  Nov;	  62(11):	  3457-­‐66	  
	  
III.  Jayesh	   M.	   Pandya*,	   Paulius	   Venalis*,	   Lubna	   Al-­‐Khalili,	   Mohammad	   Shahadat	  
Hossain,	   Vanessa	   Stache,	   Ingrid	   E.	   Lundberg,	   Vivianne	   Malmström,	   Andreas	   E.R.	  
Fasth.	  
CD28null	   T	  Cells	   from	  Polymyositis	  Patients	   are	  Cytotoxic	   to	  Autologous	  Muscle	  
Cells	  In	  Vitro	  via	  Perforin-­‐Dependent	  Mechanisms.	  
Manuscript	  
	  
IV.  Jayesh	  M.	  Pandya*,	  Ingela	  Loell*,	  Mohammad	  Shahadat	  Hossain,	  Mei	  Zong,	  Helene	  
Alexanderson,	  Sukanya	  Raghavan,	  Ingrid	  E.	  Lundberg	  and	  Vivianne	  Malmström.	  
Muscle	  Persistent	  and	   Immunosuppression	  Resistant	  CD28null	  T	  cells	   in	  Patients	  
with	  Polymyositis	  and	  Dermatomyositis.	  
Manuscript	  
	  
	  
*	  These	  authors	  contributed	  equally.	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
  
RELATED PUBLICATION NOT INCLUDED IN 
THESIS 
	  
Ingela	   Loell,	   Li	   Alemo	   Munters,	   Jayesh	   Pandya,	   Mei	   Zong,	   Helene	   Alexanderson,	  
Andreas	  E	  Fasth,	  Christina	  Ståhl	  Hallengren,	  Olof	  Rådmark,	  Ingrid	  E	  Lundberg,	  	  
Per-­‐Johan	  Jakobsson,	  Marina	  Korotkova.	  
Activated	   LTB4	   pathway	   in	   muscle	   tissue	   of	   patients	   with	   polymyositis	   or	  
dermatomyositis.	  	  
Annals	  of	  the	  Rheumatic	  Diseases	  2013	  Feb;72(2):293-­‐9	  	  
CONTENTS 
1 General introduction ................................................................................................ 1 
2 Background ................................................................................................................ 2 
2.1 Idiopathic inflammatory myopathies ........................................................................... 2 
2.1.1 Introduction ............................................................................................................... 2 
2.1.2 Classification criteria ................................................................................................. 2 
2.1.3 Epidemiology and clinical manifestations ................................................................ 2 
2.1.4 Histopathology of disease subsets ............................................................................ 5 
2.1.5 Role of T cells in IIM pathogenesis .......................................................................... 6 
2.1.6 Viral triggers .............................................................................................................. 7 
2.1.7 Treatment in IIM subtypes ........................................................................................ 8 
2.1.8 Treatment resistance and persistence of immune infiltrate in muscle tissue ........... 8 
2.2 Glucocorticoid effects ................................................................................................... 10 
2.2.1 Mechanisms of glucocorticoids action ................................................................... 10 
2.2.2 Immunosuppressive effects of glucocorticoids on T cells ..................................... 11 
2.2.3 Adverse effects of glucocorticoids on skeletal muscle and other organs .............. 11 
2.3 Skeletal muscle structure, function, homeostasis and interaction with immune 
system ....................................................................................................................................... 13 
2.3.1 Skeletal muscle structure & function ...................................................................... 13 
2.3.2 Myonuclei and myonuclear domain ....................................................................... 14 
2.3.3 Muscle injury and cell death pathways ................................................................... 14 
2.3.4 Skeletal muscle cell death in inflammatory myopathies ........................................ 16 
2.3.5 Muscle tissue repair/regeneration and role of immune system .............................. 17 
2.3.6 Difference in muscle inflammation between acute and chronic muscle injuries: 
Breaking of self-tolerance and role of T cells ..................................................................... 18 
2.3.7 Impairment of muscle regeneration in chronic muscular degeneration ................. 19 
2.3.8 Myotoxic factors in immune system ....................................................................... 19 
2.3.9 Role of skeletal muscle in immune regulation ....................................................... 21 
2.3.10 Muscle cells in culture: Myoblasts and myotubes ............................................... 22 
2.4 FOXP3+ regulatory T cells ......................................................................................... 24 
2.4.1 Role of FOXP3+ regulatory T cells in skeletal muscle regeneration .................... 24 
2.5 CD28null T cells ............................................................................................................ 26 
2.5.1 Definition CD28null T cells .................................................................................... 26 
2.5.2 Aging and CD28 co-receptor on T cells ................................................................. 28 
2.5.3 Co-stimulatory receptors on CD28null T cells ....................................................... 29 
2.5.4 Origins of CD28null T cells .................................................................................... 29 
2.5.5 Molecular and functional features of CD28null T cells ......................................... 30 
2.5.6 CD8+CD28null T cells ........................................................................................... 32 
2.5.7 CD4+CD28null T cells ........................................................................................... 33 
3 Aims .......................................................................................................................... 35 
4 Methods .................................................................................................................... 36 
5 Results and discussion ............................................................................................ 37 
5.1 CD28null T cells in patients with polymyositis and dermatomyositis (Paper-I) .. 37 
  
5.1.1 Evaluation of frequency, phenotypic and functional potential of CD28null T cells
 37 
5.1.2 Clinical relevance .................................................................................................... 39 
5.1.3 Link with Human Cytomegalovirus ....................................................................... 39 
5.2 CD28null T cells in patients with sporadic inclusion body myositis (Paper-II) .... 40 
Frequency, clonal expansions and functional evaluation .................................................... 40 
5.3 Myotoxic potential of CD28null T cells and the mechanisms involved (Paper-III)
 41 
5.4 Effects of immunosuppression on T cell subsets in IIM (Paper IV) ....................... 42 
5.4.1 Effects of conventional immunosuppressive treatment on CD28null and 
regulatory T cell subsets in muscle tissue of PM and DM .................................................. 42 
5.4.2 In vitro immunosuppressive effects of glucocorticoids and regulatory T cells on 
CD28null T cell subsets ....................................................................................................... 43 
5.4.3 Clinical relevance of persistent CD28null T cells in myositis muscle tissue ........ 44 
6 Thesis summary and cumulative discussion ........................................................ 45 
6.1 The proposed model ..................................................................................................... 47 
7 Conclusions .............................................................................................................. 51 
8 Furture perspectives ............................................................................................... 52 
9 Acknowledgements ................................................................................................. 57 
10 References ............................................................................................................. 61 
 
  
LIST OF ABBREVIATIONS 
APC 
CD 
CCR 
CCL 
CMV 
CK 
CTLA-4 
CXCR 
DM 
DMD 
Antigen Presenting Cell 
Cluster of Differentiation 
CC Chemokine Receptor 
CC Chemokine Ligand 
Cytomegalovirus 
Creatine Kinase 
Cytotoxic T-lymphocyte-Associated Protein 4 
CXC Chemokine Receptor 
Dermatomyositis 
Duchenne Muscular Dystrophy 
EBV 
FACS 
FI 
FOXP3 
GCR 
GrB 
HAQ 
HCMV 
HCV 
Epstein–Barr virus 
Fluorescence-activated Cell Sorting 
Functional Index 
Forkhead box P3 
Glucocorticoid receptor   
Granzyme-B 
Health Assessment Questionnaire 
Human Cytomegalovirus 
Hepatitis C Virus 
HIV 
HLA 
Human Immunodeficiency Virus 
Human Leukocyte Antigen 
HTLV-1 
ICAM 
ICOS 
IE-1 
IFN 
IGF-1 
IIM/IIMs 
IL 
IVIG 
Human T-cell Lymphotropic Virus Type-1 
Intercellular Adhesion Molecule 1 
Inducible T-cell COStimulator 
Immediate Early antigen-1 
Interferon 
Insulin-like Growth Factor 1 
Idiopathic Inflammatory Myopathies 
Interleukin 
Intravenous Immunoglobulins 
  
KIR 
LFA-1 
LTB4 
MAC 
mDC 
MHC 
MITAX  
MMPs 
MyHC 
NCAM 
NK-κB 
NK cell 
NO 
PBMCs 
PCR 
pDC 
PD-1 
PI3K 
PM 
pp65 
ROS 
sIBM 
SLE 
T cell 
TCR 
TNF 
tRNA 
TUNEL 
 
Killer Inhibitory Receptors 
Lymphocyte function-associated antigen 1 
Leukotriene B4  
Membrane Attack Complex 
Myeloid dendritic cell 
Major Histocompatibility Complex 
Myositis Intention To Treat Activity Index 
Matrix Metalloproteinases 
Myosin Heavy Chain 
Neural Cell Adhesion Molecule 
Nuclear Factor kappa B 
Natural Killer cell 
Nitric Oxide 
Peripheral Blood Mononuclear Cells 
Polymarase Chain Reaction 
Plasmacytoid Dendritic Cells 
Programmed cell death protein 1 
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
Polymyositis 
Phosphoprotein 65 
Reactive Oxygen Species 
sporadic Inclusion Body Myositis 
Systemic Lupus Erythematosus 
T lymphocytes 
T cell receptor 
Tumor necrosis factors 
Transfer RNA 
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
 
 

  1 
1 GENERAL INTRODUCTION 
Inflammatory myopathies are a group of diseases characterized by progressive muscle 
weakness along with chronic muscle inflammation. These diseases are also known as 
idiopathic inflammatory myopathies (IIMs) or collectively as myositis. "Idiopathic" 
means that the cause is not known and "myositis" means muscle inflammation. Several 
findings indicate that IIMs may belong to immune-mediated inflammatory diseases 
category, where the immune system, which usually protects our body from diseases 
caused by infections or cancer, cause excessive inflammation in body's organs and 
tissues, leading to functional impairment. Abnormal and chronic inflammations are the 
main features of such diseases. Prior studies have reported the abnormal presence of 
cells linked to immune system including T cells in the skeletal muscle tissue of patients 
with IIMs. However, the mechanisms underlying the initiation and progression of the 
muscle pathology and specific role of immune cells are not clearly understood. 
T cells (T lymphocytes) are specialized cells of our adaptive immune system, which 
function as key players in both maintaining immune tolerance against self-tissues and 
orchestrating multicomponent immune attack on pathogenic foreign microorganisms. 
Upon encountering a pathogen, T cell expansion takes place, and a subset of T cells 
known as memory T cells are maintained in the body to allow immediate recognition 
and effector function upon re-encounter of the pathogen. Memory T cells are thus 
equipped to kill and eradicate pathogens efficiently. However, increased frequencies of 
T cell subsets with memory phenotype, known as CD28null T cells, are reported in 
various chronic inflammatory disorders, indicating that these cells may cause 
inflammatory damage in various organs and tissue. The studies included in this thesis 
explore, whether CD28null T cell subsets can be regarded as pathogenic cells in 
inflammatory myopathies, and if yes, what could be the pathogenic mechanisms. Along 
with CD28null T cells, regulatory T cells were also investigated, which help to 
maintain self-tolerance and muscle repair. Furthermore, the effects of currently used 
immunosuppressive treatments on these T cell subsets were evaluated in patients with 
IIMs. 
The thesis attempts to introduce relevant topics adequately in the background, which 
would help reader to understand the results and discussion. The suggested pathogenic 
mechanisms are based upon previous knowledge combined with findings in this thesis. 
However, hypothesis and suggested mechanisms are my personal view and should be 
confirmed by future studies before drawing conclusions.   
 
 
 
 2 
2 BACKGROUND  
2.1 IDIOPATHIC INFLAMMATORY MYOPATHIES  
2.1.1 Introduction 
The idiopathic inflammatory myopathies (IIM/IIMs), collectively named as myositis, 
are a heterogeneous group of chronic muscle disorders, which are characterized 
clinically by skeletal muscle weakness and low endurance, and histopathologically by 
inflammatory cell infiltrates in muscle tissue 1. Based on clinical and histopathological 
differences, IIMs have been classified mostly into polymyositis (PM), dermatomyositis 
(DM) and sporadic inclusion body myositis (sIBM) 2,3.  Involvement of other organs 
than muscles is also frequently seen in DM and PM but less frequently in sIBM. 
Involvement of skin in DM, and lungs in PM and DM indicate that these myopathies 
are rather systemic connective tissues diseases 1.  
 
2.1.2 Classification criteria 
Currently, Bohan and Peter 4,5 - and Tanimoto 6 criteria are the most commonly used 
criteria for diagnosis and classification of PM and DM. These are based on clinical, 
histopathological and neurophysiological evaluation in combination with serum levels 
of muscle enzymes. However, there are several limitations to these criteria because they 
do not incorporate recently discovered molecular biomarkers such as autoantibodies, 
which could classify patients more accurately based on their disease mechanisms. The 
lack of updated classification criteria has also hampered the research and development 
of novel treatments in IIMs subtypes. Nevertheless, Bohan and Peter classification 
criteria were used for determining PM and DM included in this thesis work. The above 
criteria do not distinguish sIBM. Therefore, the criteria suggested by Grigg´s et al were 
used for sIBM classification 7,8, although we did not rely on the compulsion of electron 
microscopy evaluation.  
 
2.1.3 Epidemiology and clinical manifestations 
The PM/DM/sIBM belong to a rare clinical disease category with the incidence of 0.1–
1/100 000/year and the prevalence of 1–6/100 000/year 9. DM affects both adults and 
children and is more common in women. PM occurs mostly after second decade of life 
while sIBM mostly occurs in individuals older than 50-60 years. A male preponderance 
is observed in sIBM 9,10.  
Patients with PM and DM are described to display progressive weakness mainly of 
proximal limb muscles, while in patients with sIBM, distal muscles are often affected 
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with pronounced weakness and atrophy in addition to proximal muscles. However, a 
recent study in our group demonstrated that distal muscles are also affected in patients 
with PM and DM 11. Proximal muscle weakness presents symptomatically as 
difficulties in everyday activities such as climbing the stairs, dressing, bathing, lifting 
objects or combing hair. Distal muscle weakness presents with difficulties in buttoning 
of shirts, sewing, writing etc. In all forms of IIM, pharyngeal and neck-flexor muscles 
are usually involved, leading to difficulties in swallowing and holding up the neck. In 
advanced cases, breathing difficulties may be encountered due to involvement of 
respiratory muscles.  Severe weakness if untreated, almost always leads to muscle 
wasting. Myalgia and muscle tenderness (pain) may be present but the frequencies are 
unclear. Weakness in PM and DM progresses sub-acutely over a period of weeks or 
months and rarely acutely; by contrast sIBM muscle weakness progresses very slowly 
over years. Other common symptoms include fatigue and weight loss and malaise as a 
result of inflammation, muscle atrophy, pain and weakness. Some patients can also 
display arthralgia, arthritis, myocarditis and arrhythmias. Initial symptoms mostly 
include slow onset of muscle fatigue, but skin and lungs might also be involved. 
Increased incidences of malignancies are observed in patients with DM, particularly in 
patients older than 50 years. Symptoms can appear in different organs at different time 
points as the disease progresses. Involvement of multiple organs may lead to more 
severe complications, diagnostic difficulties, poor prognosis and reduced life 
expectancy. 9,10,12,13 (Inflammatory Myopathies. Harrison's Principles of Internal 
Medicine 16th Edition, Vol II) 
 
 
Figure 1: Skeletal muscle structure and connective tissue layers. There are three layers of 
connective tissue in a skeletal muscle. The epimysium is the outermost layer and surrounds the 
whole skeletal muscle. The perimysium surrounds the muscle fascicles and contains blood 
vessels and nerves. A fascicle contains a group of muscle fibers (between 10-100). The 
endomysium surrounds each single muscle fiber and is a thin, delicate covering of loose 
connective tissue. Endomysium also contains blood capillaries and nerves. (Picture and legend 
adapted from Wikipedia & Gray's Anatomy: IV. Myology) 
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negative effect onmuscle contractility, or apersistent
atrophy because of disuse or defectivemuscle regen-
eration. Another explanationcouldbe replacement of
muscle tissue by fat which is often seen in patients
with IBM, regardless of immunosuppressive treat-
ment. Possible molecular mechanisms that could
contributeto thepersistentchronicmuscleweakness
in polymyositis and dermatomyositis will be further
discussedbelow.
Muscle weakness inmyositis
Loss ofmuscle fibres owing tomyocytotoxic effect of immune cells
The most often advocated mechanism of muscle
weakness inmyositis is an immune-mediated loss of
muscle fibres through a myocytotoxic effect of infil-
trating inflammatory cells [6]. Muscle tissue in poly-
myositis, dermatomyositis and IBM is typically char-
acterized by infiltration of inflammatory cells; in
particular, of T cells, macrophages, dendritic cells
and occasionally B cells [2, 13]. The T-cell infiltrates
are composed of CD4+ and CD8+ T cells [2]. A direct
cytotoxic effect throughan interactionbetweenCD8+
T cells andmajor histocompatiblility complex (MHC)
class I onmuscle fibers has been suggested as a me-
chanismformusclefiberdamage inpolymyositis and
inclusionbodymyositis. However, the costimulatory
molecules required for the T cell-mediated cytotoxic
effects have not been convincingly demonstrated in
muscle tissue of myositis patients. In the light of
this, the recently demonstrated high prevalence of
CD28null T cells inmuscle tissue of myositis patients
is of particular interest as these T cells have a pheno-
type that resembles natural killer (NK) cells and can
exert a cytotoxic effect without CD28 and its ligands
[14]. It is also interesting that the NK cell properties
are observed for both CD4+ and CD8+ CD28null T
cells. Therefore, T cell-mediatedmyocytotoxicity and
loss of muscle fibres could be induced by both CD4+
and CD8+ CD28null T cells (Fig. 2), but whether
CD28null T cells really have a myocytotoic effect re-
mains tobedetermined.
Cytokine-mediatedmuscleweakness
The presence of several cytokines and chemokines
has been reported in muscle tissue of myositis pa-
tients. Cytokines have pleiotropic effects and may
have pro- or anti-inflammatory properties and there-
by serve as targets for therapy. Several different
cytokineshaveeffects onmuscle fibres, bothonmus-
cle fibre contractility and remodelling; these effects
will be the focus of the discussion in this review. The
(a)
(b)
(c)
Fig. 1 (a–c) Characteristics of healthymuscle and ofmuscle
from patients with polymyositis and dermatomyositis. (a)
Cross-sectional muscle biopsy tissue from a healthy subject
(haematoxylinandeosinstaining). Image courtesyofDrCeci-
lia Grundtman. (b) Cross-sectional muscle biopsy sample
from a patient with polymyositis; image shows fibre size
variation, several fibres with central nuclei, mononuclear
inflammatory cells with an endomysial distribution and sur-
rounding muscle fibres (haematoxylin and eosin staining),
degenerating fibres (thick arrows) and regenerating fibres
(broken arrows). Image courtesy of Dr Inger Nennesmo. (c)
Cross-sectional muscle biopsy sample from a patient with
dermatomyositis; image shows a perimysial and perivascu-
lar inflammatory cell infiltrate and perifascicular distribution
of small fibres (arrows) so-called perifascicular muscle
atrophy). Often, these smaller fibres are regenerating fibres.
ImagecourtesyofDr IngerNennesmo.
I. Loell & I. E. Lundberg | Review: Muscle weakness in myositis
ª 2011 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine 269; 243–257 245
 
Figure 2.  (a–c) Characteristics of 
healthy muscle and of muscle from 
patients with polymyositis and 
dermatomyositis. (a) Cross-sectional 
muscle biopsy tissue from a healthy subject 
(haematoxylin and eosin staining). Image 
courtesy of Dr Cecilia Grundtman. (b) 
Cross-sectional muscle biopsy sample from 
a patient with polymyosit s; image shows 
fibre size variation, several fibres with 
central nuclei, mononuclear inflammatory 
cells with an endomysial distribution and 
surrounding muscle fibres (hae atoxylin 
and eosin staining), degenerating fibre  
(thick arrows) and regenerating fibres 
(broken arrows). Image courtesy of Dr Inger 
Nennesmo. (c) Cross-sectional muscle 
biopsy sample from a patient with 
dermatomyosit s; image shows  perimysial 
and perivascular inflammatory cell infiltrate 
and perifascicular distribution of small 
fibres (arrows) so-called perifascicular 
muscle atrophy). Often, these smaller fibres 
are regen rating fibres. Image courtesy of 
Dr Inger Nennesmo. 
Figure and legend reprinted by permission 
from John Wiley & Sons. Publication: Loell 
I & Lundberg IE. Journal of Internal 
Medicine. 2011 Mar; 269(3):243-57 
Figure 3: Characteristics of muscle from 
patients with sporadic inclusion body 
myositis.               
Cross-sectional skeletal muscle biopsy 
tissue stained with Gomori Trichrome, 
which allows the visualization of the 
rimmed vacuoles, the hallmark of sporadic 
inclusion body myositis. Mononuclear 
ndomysial infiltrates which surrounds and 
sometime invade muscle fibres, are seen in 
muscle biopsy section.  Fiber sizes vary 
greatly, among which small fibers may be 
degenerating and regenerating fibers. 
(Image courtesy of Dr Inger Nennesmo). 
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2.1.4 Histopathology of disease subsets 
Muscle is the major target organ in the inflammatory myopathies, and distinct 
histopathological features among different subtypes point towards different disease 
mechanisms among subtypes.  Typically, but not exclusively, DM is characterized by 
perivascular and perimysial/perifascicular inflammatory infiltrate which is often 
associated with perifascicular atrophy (Figure 1 and Figure 2). Complement and 
membrane attack complex (MAC) deposition have been detected around the vessels in 
DM muscle 14. These findings indicate an autoimmune reaction directed against blood 
vessel leading to microvasculature destruction, followed by various muscle pathologies. 
On the contrary, PM and sIBM are characterized by endomysial inflammatory 
infiltrates at multiple foci surrounding muscle fibers (Figure 1, Figure 2 and Figure 
3), indicating a direct autoimmune attack against the muscle compartment. 1,10. In all 
subsets of IIMs, irregular sizes of fibers are observed in cross-sectional area, with many 
fibers displaying atrophic features (smaller size) (Figure 2 and Figure 3). These 
atrophic fibers often have signs of regeneration, which could reflect chronic 
degeneration and regeneration processes in these muscles 13. In sIBM, presence of 
rimmed-vacuoles is an additional feature (Figure 3), along with tiny amyloid 
deposition in or near those vacuoles, which can be identified by Crystal-violet or 
Congo-red stains 10.  
However, histopathological features of muscle tissue are not always distinct, and many 
patients display mild or no immune cells/inflammatory infiltrate in muscle biopsies 
despite pronounced muscle weakness. The absence of immune infiltrates in the muscle 
biopsies could be due to patchy nature of infiltrate. This problem to a certain extent can 
be overcome by MRI (magnetic resonance imaging) guided muscle biopsy in the areas 
with edema, which improve the chance to capture the regions with immune infiltrate 
15,16. Nevertheless, various findings suggest that both immune and non-immune 
mechanism could be in involved in muscle pathology 17,18. Moreover, sIBM muscle 
show features suggestive of many degenerative phenomena such as unfolded protein 
response, endoplasmic-reticulum stress, lysosome and mitochondrial abnormalities 19-
21.  Although, pathogenic mechanisms in different subtype of IIMs are complex and not 
clearly understood, the general understanding and proposed immune mechanisms are 
summarized in Figure 4. 
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Figure 4: Potential immune mechanisms in myositis pathogenesis. Immune activators, for 
example, respiratory infection, trigger disease in myositis susceptibility gene carriers. Other 
environmental factors might contribute. b | Innate and adaptive responses are activated in lymph 
nodes; macrophages secrete cytokines; mDCs present antigens to T cells; activated T cells 
assist B-cell activation and proliferation; some B cells differentiate into autoantibody-secreting 
plasma cells. c |Activated immune cells enter general circulation. Upon encountering specific 
antigens, immune cells penetrate endothelia, into local muscle. di | In polymyositis (and perhaps 
sIBM), CD8+ T cells expressing perforin-1 and granzyme invade non-necrotic muscle fibers 
expressing MHC class I molecules (continuous MHC expression might be induced by pDC-
derived type I IFN); mDCs activate T cells, and macrophage-derived cytokines control T-cell 
homeostasis, activation and proliferation. dii | In dermatomyositis, infiltrates—composed of 
CD4+ T cells, B cells, DCs and macrophages—usually invade perivascular and perimysial 
muscle tissue, and might organize into structures resembling lymph node germinal centers. ei 
|Immunohistochemistry of muscle tissue from a patient with polymyositis, showing CD8+ T 
cells localized to endomysium. eii | Perivascular localization of CD4+ T cells in muscle tissue 
of a patient with dermatomyositis, revealed by immunohistochemistry. Abbreviations: IFN, 
interferon; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell; sIBM, sporadic 
inclusion body myositis. (Figure and legend reprinted by permission from Nature Publishing 
Group. Publication: Zong, M. & Lundberg, I. E. (2011) Nat Rev Rheumatol. 2011 
May;7(5):297-306) 
 
2.1.5 Role of T cells in IIM pathogenesis 
When immune infiltrates are observed in muscle tissue of IIMs, they consist of mainly 
T cells, macrophages and other immune cells (less frequent). Endomysial mononuclear 
infiltrates consisting of mainly CD8+ T cells and macrophages which invade HLA 
class-I expressing non-necrotic muscle fibers, are described as typical of PM and sIBM 
muscle. While perimysial/perivascular infiltrates consisting mainly of CD4+ T cells 
with occasional B cells and macrophages are described as typical of DM muscle. 22-26 
However, above definitions are probably oversimplified in the context of recent 
findings, where both CD4+ and CD8+ T cells have been reported in endomysial and 
perimysial infiltrates of all IIM subtypes 27.  
In addition, several studies describe the presence of cytotoxic and cytolytic molecules 
in T cells surrounding muscle fibers in IIMs subtypes. The presence of perforin, 
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granzyme and granulysin have been detected in the T cells which invade muscle fibers 
2,28-31. Clonally expanded and perforin positive T cells have been detected in both 
peripheral blood and muscle tissue of patients with IIMs 32-34. 
The role of T cells in IIMs pathogenesis has also been supported by some recent animal 
models studies. A murine polymyositis model demonstrated that beta2-microglobulin-
null and perforin-null mutant mice display significantly lower number of myositis 
incidences along with lower muscle inflammation and injury, compared to wild type 
mice 35. The adoptive transfer of CD8+ T cells alone or CD4+ T cells alone, or in 
combination could induce myositis in naive recipient mice, although the outcome of 
disease incidence and severity varied depending on the murine models 35,36. Murine 
studies also points towards the role of FoxP3+ regulatory T (Treg) cells in myositis 
pathogenesis. Recent studies in two different myositis models demonstrate that Treg 
cells depletion leads to more severe disease, and addition of in vitro expanded Treg 
cells led to disease improvement 36,37.  
Despite above findings that imply the role of T cells in pathogenesis of myositis, the 
precise phenotype and functionality of pathogenic T cell subsets are not clearly 
understood in the setting of human inflammatory myopathies.   
 
2.1.6 Viral triggers 
Viruses are known to combat with the immune system and induce interferon 
productions 38. Several viruses are described to be indirectly associated with many 
chronic and acute myopathy conditions. Specific subtypes of coxsackievirus have been 
implicated in inflammatory myopathies 39,40 and RNA from coxsackievirus have also 
been detected in patients with PM and DM 41. However, this was contradicted by other 
studies, reporting the absence of any candidate viral genome in the muscle tissue 42,43. 
Additionally, retroviruses such as Human Immunodeficiency Virus (HIV) and Human 
T-cell Lymphotropic Virus Type 1 (HTLV-1) have been implicated in various chronic 
and acute myopathies 44-47. Infections with retrovirus have been associated with the 
development of inflammatory myopathies with features of PM and sIBM, in both 
humans and nonhuman primates 48-52. The manifestations of inflammatory myopathies 
in the retroviral-infected individuals could occur in both early and late stages of 
infection. More recently, infections with Human Cytomegalovirus (HCMV) 46,53-57, 
Epstein–Barr virus (EBV) 58,59, Hepatitis C virus (HCV) 60-66 and Hepatitis B virus 
(HBV) 67-69 have also been reported to be associated with the several forms of 
myopathies. However, the presence of candidate viral genome and viral replication in 
muscle tissue of myositis patients are controversial 10,42,54,70. Nevertheless, association 
of various viral infections with myopathies suggests that even in absence of viral 
replication within muscle, chronic viral infection may trigger a persistent inflammatory 
response, where the virus-specific T cell could play essential role in breakdown of 
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tolerance towards the muscle compartment.  However, the role of viruses and virus-
specific T cells in the pathogenesis of IIMs is not clearly understood.  
 
2.1.7 Treatment in IIM subtypes 
Due to lack of understanding of disease mechanisms, conventional myositis therapies 
are largely based on general immunosuppression. There have been very few controlled 
trials in IIM subtypes. Therefore, the treatment recommendations are largely based on 
clinical experience and open-label trials 1,71. Conventional treatment regimen for PM 
and DM includes high doses of glucocorticoids 0.75–1.00 mg/kg per day, most often 
for several weeks. Response to such treatment is seen in many patients, however side 
effects are common, and the recovery of former physical and muscle functions are rare. 
Therefore, more recently, many experts recommend combination therapies by including 
another immunosuppressive/s in order to improve the response and reduce the need for 
steroids. The frequently used first line drugs for combination therapies are methotrexate 
at 15-25mg/week or azathioprine at 2mg/kg per day.1  In case of adverse events, second 
line drugs are cyclosporin-A, with equal potency as methotrexate 72 or mycophenylate 
mofetil based on various case reports 73,74. Glucocorticoids interfere with signaling 
pathways related to immune activation and at high doses, capable of inducing apoptosis 
in immune cells including T cells 75 76. The mechanisms of action of glucocorticoids 
and specific effects on T cells have been described in section 1.3. Additional 
immunosuppressives such as methotrexate, azathioprine, cyclosporine-A and 
mycophenylate mofetil, mainly block the proliferative properties of immune cells 77. 
Patients refractory to first line or above treatments are sometime given intravenous 
immunoglobulins (IVIG) 71. IVIG is derived from large pools of donated human 
plasma and known to have immunosuppressive effects.  However, the response to IVIG 
treatment is also variable. Some steroid-resistant patients with esophageal involvement 
show good response, however many patients do not respond to IVIG.78-81 In contrast to 
PM and DM, above-mentioned immunosuppressive treatments usually fails in sIBM 
patients and currently, there is no effective treatment for sIBM 10,81,82.  
 
2.1.8 Treatment resistance and persistence of immune infiltrate in 
muscle tissue 
Ineffectiveness of conventional immunosuppressive therapies in IIMs is also reflected 
in histopathology, as the inflammatory infiltrates in muscle tissue persist in several 
patients despite aggressive treatment. The persistent inflammatory infiltrates and 
inflammatory markers have also been shown to be associated with remaining muscle 
weakness 83-85.  
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Although, T cells are implicated in the IIM pathogenesis, whether specific subsets of T 
cells could persist in IIM muscle despite aggressive immunosuppressive treatment, and 
may escape apoptotic and immunosuppressive effects of glucocorticoids, is not known. 
My thesis attempts to address these questions, in the context of conventional 
immunosuppressive treatments (glucocorticoids alone or combination with additional 
immunosuppressive drugs). Effects of IVIG are previously studied by our group 86, and 
not part of this thesis. Barbasso Helmers and colleagues demonstrated that high doses 
of IVIG had only limited effects on the molecular markers and immune cells associated 
with inflammation in muscle tissue, and T cells were present in equal degree before and 
after IVIG treatment. 
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2.2 GLUCOCORTICOID EFFECTS 
Glucocorticoids belong to a class of steroid hormones, which regulate a variety of 
important biological functions 87. Endogenous glucocorticoids exert various kind of 
immunomodulatory activity including the control of T cell homeostasis 76. Due to their 
profound anti-inflammatory and immunosuppressive effect as well as the property to 
induce lymphocyte apoptosis, synthetic glucocorticoids are among the most commonly 
prescribed drugs worldwide.  
 
2.2.1 Mechanisms of glucocorticoids action 
The effects of glucocorticoids are pleiotropic, dose-dependent and not fully understood. 
These effects can be either genomic or non-genomic in nature 88.  The genomic effects 
are largely believed to be responsible for many anti-inflammatory and 
immunoregulatory effects, however such effects are described to take many hours to 
many days 88,89. Therefore, the immediate therapeutic effects of glucocorticoids are 
thought to be mediated through non-genomics effects 90.  
2.2.1.1 Non-genomic effects 
At high doses of glucocorticoids (prednisone-equivalent dose of >30 mg per day) 91, 
three different mechanisms can lead to non-genomic effects 88. Non-specific interaction 
of glucocorticoids with cell membrane or membrane associated proteins, which can 
hinder the functions of immune cells such as proliferation, migration, phagocytosis and 
antigen presentation 89. The specific interaction with glucocorticoid receptors  (GCRs), 
where interaction with membrane-bound GCR can inhibit T cell receptor signaling 92, 
or interaction with cytosolic GCR can inhibit arachidonic acid pathway 93.   
2.2.1.2 Genomics effects 
Genomic effects of glucocorticoids are better characterized than non-genomic effects. 
The binding of inactive cGCR with glucocorticoids convert them into active cGCR, 
which translocate into nucleus and binds to specific DNA binding sites known as 
glucocorticoid responsive elements. The binding of cGCR-glucocorticoid complex at 
glucocorticoid responsive elements can either induce or inhibit transcription, the 
processes known as transactivation or transrepression respectively 94.  Anti-
inflammatory effects are believed to occur mostly through transrepression events, 
which involves interference in binding or functions of transcription factors involved in 
inflammatory pathways. On the contrary, adverse effects of glucocorticoids are mostly 
assigned to transactivation events. 88,95,96 
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2.2.2 Immunosuppressive effects of glucocorticoids on T cells  
During thymic selection of T cells in mice, glucocorticoid-induced apoptosis is one of 
the major mechanisms responsible for the negative selection of self-reactive double 
positive (CD4+CD8+) thymocytes, due to their high sensitivity towards glucocorticoid-
induced apoptosis 87,97. Mature T cells are considered rather less sensitive to 
glucocorticoid-induced apoptosis 98. Nevertheless, murine studies show that 
glucocorticoids can induce apoptosis in mature T cells also via membrane-bound GCR, 
however the density of membrane-bound GCR on T cells is critical rather than merely 
the expression. 99 100 
Instead, immunosuppressive effects of glucocorticoids on T cells are largely mediated 
through various other pathways than apoptosis. For example, T cell proliferation upon 
mitogenic stimuli can be inhibited by glucocorticoids. Glucocorticoids have been 
shown to interfere with the expression of large number of cytokines, thereby affecting 
T cell proliferation and functions. 76 Other effects of glucocorticoids on T cells includes 
down-regulation of surface adhesion molecules e.g., ICAM-1 and E-selection 101; 
Inhibition of CD40 ligand upregulation on activated CD4+ T cells 102; Interference with 
granzyme-B transcription and early T cell Receptor (TCR) signaling events. Most of 
the data concerning the effects of glucocorticoids on T cells comes from murine 
studies, so the effects on human cells could vary compared to mice.   
2.2.2.1 Effect of glucocorticoids on different T cell subsets in human 
The role of glucocorticoids in the regulation of human T cell subsets remains 
controversial. Glucocorticoids induced polarization of naïve T cells towards a Th2 and 
regulatory T cell phenotype has been reported by some studies 103,104. Also, treatment 
with glucocorticoids has been reported to increase peripheral regulatory T cells and 
FOXP3 levels in diseases such as asthma and systemic lupus erythematosus (SLE).105-
107 Contrastingly, intra-articular glucocorticoid treatment decreased both the number 
and the frequency of FOXP3+ regulatory T cells in synovial tissue of rheumatoid 
arthritis patients 108. Another study describes no effect on regulatory T cells upon oral 
glucocorticoid treatment in asthmatic patients 109. In general, effects of glucocorticoids 
on mature and effector human T cell subsets remain largely unclear. Also, it was not 
known how glucocorticoids based immunosuppressive treatment affects different T cell 
subsets in IIM muscle tissue. 
 
2.2.3 Adverse effects of glucocorticoids on skeletal muscle and other 
organs 
Prolonged uses of glucocorticoids are associated with several adverse effects such as 
osteoporosis, weight gain, adrenal suppression leading to steroid-induced Cushing's 
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syndrome, systemic arterial hypertension, cataracts, metabolic syndromes and catabolic 
effects on skeletal muscle 110. These adverse effects are dependent on the 
glucocorticoid dose and the duration of therapy as well as genetic predisposition of 
patients, which govern the saturation level of glucocorticoid receptors and susceptibility 
towards these effects 111. Importantly, upon prolonged exposure, glucocorticoids may 
have detrimental effect on the homeostasis of skeletal muscle itself, mainly via 
inducing catabolic effects and interfering with muscle regeneration process. Such 
adverse effects could result in exaggerated muscle weakness referred to as ‘steroid 
myopathy’. The catabolic effects of glucocorticoids on skeletal muscle are mediated 
largely via affecting two pathways which are linked to regulation of muscle mass, (i) 
IGF-1-PI3K-Akt pathway, which induces muscle protein synthesis and increase in 
muscle mass, and (ii) myostatin signaling pathway, which is a negative regulator of 
muscle mass. Normally, IGF-1 pathway dominantly inhibits the myostatin signaling 
pathway, however glucocorticoids block the effects of the IGF-1 pathway as well as 
upregulate catabolic effects of myostatin pathway, leading to a coupled effect on the 
induction of skeletal muscle catabolism. 88,112  
Skeletal muscle holds the capacity to regenerate upon injury, where immune cells play 
crucial role in muscle repair process (described in section 1.4.5). However, 
glucocorticoids can negatively affect muscle regeneration process via interfering with 
differentiation of myoblasts and /or disrupting the immune response involved in muscle 
repair process 88,113,114.  
In conclusion, although glucocorticoids are aimed at dampening the 
inflammation/immune cell mediated muscle damage in inflammatory myopathies, the 
adverse effects of glucocorticoids on skeletal muscle itself cannot be ignored. 
Therefore, development of improved and specific therapies for patients with 
inflammatory myopathies is highly recommended.  
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2.3 SKELETAL MUSCLE STRUCTURE, FUNCTION, HOMEOSTASIS AND 
INTERACTION WITH IMMUNE SYSTEM  
 
2.3.1 Skeletal muscle structure & function 
Skeletal muscle constitutes up to 50% of total body mass, making it the largest organ in 
the human body. Skeletal muscles are the tissue structure specialized to generate 
mechanical force, and are made up of thousands of skeletal muscle fibers (myofibers), 
that are bundled together and attached to bones by tendons (Figure 5) 115. Myofibers 
are large syncytial (multi-nucleated) cells, generated during development by the fusion 
of mononucleated myoblasts. Myofibers are covered by a specialized plasma 
membrane known as sarcolemma, which connects and propagate signals from motor 
neurons and other external stimuli into muscle fibers.  Myofibers are surrounded by a 
layer of extracellular matrix known as the basement membrane, which constitute both 
an internal basal lamina and an external reticular lamina 116.  In the protective niche 
between sarcolemma and basal lamina, the muscle regenerative cells (satellite 
cells/muscle stem cells) resides, which can proliferate and differentiate into myoblast 
helping muscle repair.  
 
 
Figure 5.  Skeletal muscle structure and composition. Skeletal muscle is composed of 
numerous bundles of muscle fibers. Each bundle consists of multiple fibers, and individual 
fibers encompass many myofibrils. Sarcomeres are the structural units of myofibrils and are 
made up of actin and myosin filaments. Abbreviation: T-tubule, transverse tubule. (Figure and 
the legend reprinted by permission from Annual Reviews. Publication: Tabebordbar M et al., 
Annu. Rev Pathol. 2013 Jan 24;8:441-75). 
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The contraction of muscle fibers is calcium-dependent, which is facilitated by a 
specialized cytoplasm known as sarcoplasm and modified endoplasmic reticulum (ER) 
know as sarcoplasmic reticulum (SR). The sarcolemma is enclosed with Transverse 
tubules (T-tubules) facilitating the propagation of action potentials and activation the 
SR thoroughly. Myofibers contain many myofibrils acting as contraction units and are 
surrounded by SR. Myofibrils constitute thin myofilaments (actin) and thick 
myofilaments (myosin) which leads to striated appearance of skeletal muscle in the 
microscope.  Actin filaments make up the light band (I-band), and myosin filaments 
make up the dark band (A-band) (Figure 5). The structure between two Z-lines 
constitutes one sarcomere, which is the structural unit of the myofibril 117. 
The depolarization of the sarcolemma via action potential initiates the muscle 
contraction process. The depolarization induces opening of sarcoplasmic calcium 
channels, leading to increase in the intracellular calcium concentration. This triggers the 
calcium-dependent movement of actin verses myosin filaments leading to contraction 
of sarcomeres, collectively generating the muscle contraction. The transmission of 
contraction signals from myofibers to the extracellular matrix and to neighboring 
myofibers is mediated through protein assemblies known as costameres. 115  
 
2.3.2 Myonuclei and myonuclear domain  
Muscle fibers are post-mitotic cells and are unable to divide and replicate. Myonuclei 
are essential for skeletal muscle homeostasis, maintenance and adaptive responses 118.  
The theory of myonuclear domain suggests that each skeletal muscle nucleus controls 
an area of surrounding cytoplasm 119 and supports sufficient protein production in 
limited area of local “domain” 120. Myonuclear domain size is different for fast and 
slow fiber types due to difference in protein turnover rate and oxidative capacity 121. 
Nevertheless, the number of myonuclei can increase or decrease in different situations 
such as, increase in response to muscle growth, hypertrophy or overload and decrease 
in case of muscle atrophy. 118. 
 
2.3.3 Muscle injury and cell death pathways 
2.3.3.1 Acute and contraction-induced muscle damage 
Acute muscle injury can occur due to physical and chemical insults, which can induce 
rapid myofiber necrosis. Various myotoxins such as in bee or snake venoms mostly 
disrupts the integrity and function of sarcolemma leading to subsequent necrosis 115. 
There could be several other causes of acute and contraction-induced muscle injuries, 
however such mechanisms of muscle damages are beyond the scope of this thesis.  
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2.3.3.2 Role of autophagy muscle homeostasis 
In addition to providing mechanical force, skeletal muscles are also one of the most 
important sites for the control of metabolism in mammals. During catabolic 
conditions, mobilizations of muscle proteins to liver for gluconeogenesis, functions as 
the alternative energy source for other organs. In this context, the ubiquitin-proteasome 
and autophagy-lysosome systems are emerging as the major proteolytic pathways in 
atrophying muscles 122.  
The arrangements of various organelles and contractile proteins are different in muscle 
fibers compared to mononuclear cells. For example mitochondria and sarcoplasmic 
reticulum and contractile proteins are embedded among the myofibrils in comparison to 
cytosol localization in other cells. Physical mobility requires enormous energy 
generated by the muscle mitochondria by production of reactive oxygen species (ROS). 
The ROS production can have harmful effects on many cellular components. Therefore, 
muscle cells require an efficient system for the clearance of unfolded proteins, toxic 
byproducts and dysfunctional organelles. Recent findings indicate that autophagy 
pathway play important role in muscle homeostasis 122.  
In autophagy, double membrane vesicles are generated which engulf portion of 
cytoplasm, organelles, glycogen and protein aggregates 123 124.  Autophagosomes are 
then fused to lysosomes in order to degrade the contents inside.  Impaired autophagy 
either causes accumulation of abnormal organelles and toxic proteins or excessive 
degradation of muscle proteins, both of these can lead to myofiber degeneration and 
myopathies 125. For example, the accumulation of non-digested autophagosomes forms 
the morphological structures known as rimmed vacuoles and induces protein 
aggregation 126, similarly to vacuoles in muscle of sIBM patients.  A recent study also 
shows that altered expression of genes involved in autophagy are linked to impaired 
muscle remodeling in chronic hemiplegic human skeletal muscle 127.  However, the role 
of autophagy in the control of muscle cell homeostasis has not been understood 
substantially. 
 
2.3.3.3 Apoptosis and necrosis in skeletal muscle fibers 
Apoptosis is one of the most important mechanisms of programmed cell death in 
mononuclear cells, and is characterized by cytoplasmic and nuclear condensation, DNA 
fragmentation, and formation of apoptotic bodies and maintenance of an intact plasma 
membrane during cell death 128. An important feature of apoptosis is the rapid clearance 
of these apoptotic bodies by resident phagocytes, which prevents tissue from harmful 
inflammatory response.  On the contrary, necrosis has been described as uncontrolled 
release of cellular components due to processes such as swelling and membrane 
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breakdown, leading to inflammatory response associated with macrophage activity. In 
the absence of phagocytosis, apoptotic bodies could proceed towards lysis, which is 
termed as secondary or apoptotic necrosis. The loss of membrane integrity in other 
processes of cells death such pyroptosis and oncosis could also leads to necrosis 128.   
In multinuclear cells such as skeletal muscle fiber, presence of apoptosis is less evident 
and various data are conflicting and unclear.  According to some reports, apoptosis 
generally affects single nuclei rather than inducing the death of the entire myofiber 129.  
Such process has been named as nuclear apoptosis and is suggested to have negative 
effects on gene expression in the myonuclear domain. In contrast, other reports indicate 
that myogenic cells such as satellite cells and myoblasts are more sensitive to oxidative 
stress and pro-apoptotic factors compared to well-differentiated cells, such as myotubes 
and myofibers 130-132. 
While, light microscopic examination reveals muscle fiber necrosis in many disease 
states, apoptotic cell death is much less evident 133. Although it is not fully understood, 
autophagy seems to play important role in muscle homeostasis in normal conditions as 
described above, while the muscle fiber necrosis is mostly indicative of pathological 
state 134.  The role of apoptosis in skeletal muscle homeostasis is unclear and whether 
apoptosis plays any role in pathogenesis of inflammatory myopathies, is not known.  
 
2.3.3.4 Effect of age and systemic environment on skeletal muscle 
Studies with single fiber and in vitro motility assays indicate that part of 
the muscle dysfunction in aged individuals is due to increased post-translational 
modifications in proteins such as myosin 135.  The chance of post-translational 
modifications of proteins increases due to lower protein turnover rates.  Also, the 
impaired regenerative capacity of old muscles has been linked with lower 
differentiation capacity of satellite cells. Interestingly, the satellite cells from older 
individual display improved myogenic capacity in the presence of serum from young 
individuals, indicating the importance of systemic environment in muscle regeneration 
136. It has also been shown that systemic inflammation and cytokines such as TNF not 
only suppresses satellite cell differentiation but also induces apoptosis in satellite cells 
137. Therefore, systemic inflammation such as in patients with PM and DM, and age 
related factors could negatively affect muscle regeneration process. 138 
 
2.3.4 Skeletal muscle cell death in inflammatory myopathies 
Necrosis has been reported as cell death mechanism in inflammatory myopathies by a 
number of studies so far. Although, in PM and sIBM, classical histopathological picture 
shows the presence of CD8+ T cells attacking the muscle fibers, and therefore one 
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would expect to see signs of apoptotic cell death in muscle fibers. However, majority of 
studies do not find any evidence of apoptosis in the muscle fibers of patients with 
inflammatory myopathies 132,133,139-144. There are some contradictory findings, where it 
is often difficult to distinguish TUNEL staining in myonuclei compared to staining in 
infiltrating cells in those studies 145 and the positive TUNEL staining could belong to 
infiltrating cells.  
Also, there are contradictory data regarding expression of apoptosis related factors in 
myositis muscle tissue. Although, expression and upregulation of pro-apoptotic factors 
such as Fas have been reported in myositis muscle tissue, the co-expression of anti-
apoptotic molecules such as Bcl-2, FLICE (Fas-associated death domain-like IL-1- 
converting enzyme)-inhibitory protein (FLIP) and IAP (inhibitor of apoptosis proteins) 
explain the apoptosis resistant nature of myofibers in inflammatory myopathies 
132,139,140,143,145-147.   
Proinflammatory cytokines such as TNF, IL-1β, and IFNγ induce autocrine nitric oxide 
(NO) production in cultured muscle cells, leading to oxidative damage 148. Indeed, 
muscle fibers in myositis display increased levels of inducible and neuronal nitric oxide 
synthase (NOS) 149. The NO induced oxidative stress may not only induce muscle fiber 
necrosis but may also lead to decreased ATP generation and contractile function 150. In 
addition, recent findings indicate that impaired autophagy could also play a role in the 
pathogenesis of myositis, if not in all, at least in some subtypes 1,19,21,151,152, which could 
be linked to ER stress 1. However, the exact mechanisms (immune or non-immune) that 
are primarily responsible for the pathogenesis of inflammatory myopathies remain 
unknown.  
 
2.3.5 Muscle tissue repair/regeneration and role of immune system 
Muscle fibers, like many eukaryotic cells, have the capacity to repair minor membrane 
damages using membrane patch. Defects in muscle membrane repair lead to various 
forms of myopathies, for example, mutation in dysferlin is linked to limb-girdle 
muscular dystrophy type 2B and Miyoshi myopathy 153. In inflammatory myopathies 
too, the leakage of creatine kinase (CK) indicate muscle membrane damage and/or 
impairment in membrane repair process. However, detailed mechanism and role of the 
other proteins in muscle membrane repair is poorly understood and out of the scope of 
this thesis.  
In most instances post injury, skeletal muscle repair is mediated via satellite cell muscle 
regeneration and remodelling processes 13,115,154. Satellite cells are unipotent adult 
muscle stem cells which proliferate and differentiate into myoblasts in response to 
muscle damage. The myoblasts fuse with damaged myofibers or with one another to 
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generate new myofibers. Satellite cells contain self-renewal capacity which maintain 
themselves in the muscle tissue throughout lifespan in order to help muscle repair 155.   
Satellite cells normally are in a mitotically and metabolically quiescent state, however, 
become activated in response to injury or chronic muscle degeneration.  Muscle tissue 
damage leads to release of various growth factors and cytokines from extracellular 
matrix and neighboring endothelial, interstitial  and immune cells that trigger the 
proliferation of satellite cells 156,157. In addition to tissue growth factors and cytokines, 
the infiltrating immune cells and resident fibro-adipogenic precursors (FAPs) also 
affect the outcome of satellite cell muscle regeneration process. The regenerative 
capacity of satellite cells is impaired in the absence of infiltrating immune cells 158, 
indicating the essential roles of immune cells in muscle repair. However inappropriate 
or excessive immune infiltration could adversely affect the regeneration process.  
Among immune cells, neutrophils are recruited first, followed by M1 macrophages and 
thereafter M2 macrophages 159. With the interaction with neutrophils, M1 macrophages 
can further promote muscle damage by producing of high levels of NO and 
inflammatory cytokines 160. In contrast, M2 macrophages are involved in tissue repair 
and are described to be anti- inflammatory. Both neutrophils and macrophages are 
described to participate in clearance of cellular debris after injury and inflammatory 
damage. The M2 macrophages in particular induce satellite cell activation and 
proliferation and further regulate muscle cell regeneration and remodeling 161.  
 
2.3.6 Difference in muscle inflammation between acute and chronic 
muscle injuries: Breaking of self-tolerance and role of T cells 
In response to acute muscle injury, usually a stereotypical inflammatory response is 
followed by repair process, as described above. In contrast, chronic muscle damage 
leads to a rather different and more complex process, which is relatively less 
understood 161. It is believed that the major difference lies in the breakdown of 
tolerance towards muscle compartment in chronic muscle injuries, which is very 
unlikely in acute injuries. Most knowledge about muscle-immune system interaction in 
chronic muscle damage arises from studies on mdx mouse model. The mdx mouse 
model is a commonly used animal model of Duchenne’s Muscular Dystrophy (DMD). 
Similar to DMD in human, mdx mice have loss of function mutation in dystrophin 
gene, which leads to progressive muscle degeneration, necrosis and chronic muscle 
inflammation 162. Dystrophin is a rod shaped cytoplasmic protein and vital part of 
protein complex costamere involved in maintaining the integrity of muscle.  
The reduction of mdx pathology upon depletion of CD4+ and CD8+ T cells and in the 
perforin mutant mice, and the transfer of muscle pathology from mxd mice to healthy 
mice by adoptive transfer of muscle primed immune cells, collectively demonstrates 
the significant role of both CD8+ and CD4+ T cells in chronic muscle destruction 
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163,164. Also, as described in IIM section (1.2.5), both human and murine studies point 
towards pathogenic role of T cells in inflammatory myopathies.  
However, it is not clear, how this breakage of tolerance occurs in patients with 
myositis, where skeletal muscles are considered normal regarding any genetic defect. 
Which subsets of CD4+ and CD8+ T cells could play role towards breakage of 
tolerance and muscle damage in myositis? The studies included in this thesis aim to 
characterize precise phenotype and functionality of T cell subsets, which could lead to 
chronic inflammation in muscle tissue.  
 
2.3.7 Impairment of muscle regeneration in chronic muscular 
degeneration 
Chronic inflammation or chronic muscular degeneration may lead to satellite cell 
exhaustion, thereby impairing the regeneration process. The reason for this exhaustion 
is most likely due to proliferation-induced telomere shortening and damage associated 
cell attrition 165,166.  A faulty muscle regeneration process usually leads to fibrosis and 
fat tissue accumulation, which further impairs the regeneration process 167.  In fact, 
signs of muscle fiber degeneration and regeneration, fibrosis and fat tissue 
accumulation are commonly seen in myositis 13. However, it is not understood, whether 
a major defect lies in muscle regeneration or immune mediated muscle damage in 
inflammatory myopathies.  
 
2.3.8 Myotoxic factors in immune system 
2.3.8.1 Granzyme-B 
Granzymes belong to a family of conserved serine proteases, which are usually stored 
within cytotoxic granules of cytotoxic lymphocytes and known to be involved in 
immune cell mediated targeted cell death 168. There are 11 granzymes in mice and 5 
granzymes in humans known so far, among which granzymes-B (GrB) is one of the 
most abundant and most studied subtype.  Previously believed only to be expressed by 
Natural Killer cells (NK cells) and CD8+ T cells, recent findings show that GrB can be 
expressed by many other cell types too such as CD4+ T cells, regulatory T cells, 
neutrophils, basophils, mast cells, macrophages, dendritic cells and many non-immune 
cells 168. The protease inhibitor-9 is the only known endogenous inhibitor of GrB, 
which is expressed mainly by immune cells in order to prevent accidental GrB 
mediated apoptotic cell death 169.  Conventionally, GrB is known for its involvement in 
perforin-dependent intracellular apoptosis in target cells. However, recently it has been 
shown that GrB could also have many extracellular, perforin independent and apoptosis 
independent roles 168.  
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2.3.8.2 Perforin and its role in granzyme entry into target cells 
It is well established that in cytotoxic lymphocytes, GrB is released towards target cells 
along with perforin via the polarization of cytotoxic granules in the direction of 
immunological synapse 170. Perforin is a calcium dependent pore forming protein which 
can form 5-20nm pores in plasma membrane upon multimerization 171. Traditionally, it 
was believed that perforin directly facilitates the entry of granzymes into target cells by 
formation of pores in target cell membrane. However, recent models suggest that GrB 
may be endocytosed by the target cells independent of perforin. Thereafter, GrB is 
released from endosomes into cytosol in perforin-dependent mechanism and leads to 
initiation of apoptosis cascade 172-174. So far, a role of perforin beyond granzyme entry 
facilitation is not known. Perforin deficiency is associated with impaired lymphocyte 
cytotoxicity in both human and mice, which confirms the role of perforin in cytotoxic 
lymphocytes-induced granzyme mediated apoptosis. 168  
In the context of perforin-granzyme mediated cell death in muscle fibers, the role of 
perforin in muscle fiber death has been confirmed by several murine studies 35,163.  
Although, classical apoptosis pathways may be rare or absent in muscle fibers, based 
on the histological evidences in myositis, it appears that perforin-granzyme could lead 
to direct necrosis and additional cell death pathways in muscle fibers. However, such 
mechanisms need to be confirmed by future studies.    
 
2.3.8.3 Extracellular granzyme-B activities.  
Recently, several groups have reported the presence of GrB in various extracellular 
matrix (ECM) and body fluids 168. The reported median levels of GrB in the plasma of 
healthy individuals is 20-40 pg/ml 175,176, whereas increased levels of extracellular GrB 
have been reported in inflamed tissue of various chronic inflammatory conditions such 
as synovial fluid in rheumatoid arthritis, bronchoalveolar lavage (BAL) in chronic 
obstructive pulmonary disease (COPD) and lung inflammation, and the cerebrospinal 
fluid in multiple sclerosis 177,178. GrB is suggested to also have various extracellular 
functions such as cleavage of ECM proteins, which could be linked to various 
pathologies.  The mechanism responsible for higher levels of extracellular GrB is not 
fully understood, whether it is leaked from immunological synapse spaces or released 
systemically in response to other stimuli. 
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2.3.8.4 Role of granzyme-B in myositis: 
The presence of GrB and perforin expressing cells in the endomysial site of myositis 
patients suggest a role of GrB in muscle fiber damage and necrosis 31. In addition, GrB 
could promote autoantibody production against certain proteins such as histidyl-transfer 
RNA synthetase and PMS-1, by exposing immunogenic epitopes of autoantigen upon 
cleavage 179-182. Interestingly, GrB specific cleavage occurs mainly in cases where 
protein conformation is altered compare to normal. These findings indicate potential 
role of GrB in regulation of many events in vivo such as cell signaling, cell death 
pathways and tissue homeostasis.  
 
2.3.8.5 Effect of TNF on muscle damage and repair 
The effect of TNF in muscle inflammation and repair is complex. Impairment of 
muscle repair in TNF knockout mice point towards an essential role of TNF in muscle 
regeneration and homeostasis 183,184.  However, TNF has also been implicated in 
inducing muscle damage and inhibiting muscle repair process through various 
mechanisms. 161 Several findings demonstrate that TNF effects on muscle cells are 
mediated mainly via induction of NF-κB expression 185,186.  NF-κB induction in both 
macrophages and muscle cells directly or indirectly affects muscle cell proliferation 
and differentiation. In most instances, NF-κB activation increases proliferation and 
inhibits differentiation of muscle cells. TNF is also known to induce NO productions 
by myeloid cells and other immune cells, which can cause muscle fiber damage 184. 
However, dual effects of TNF on muscle damage and repair processes, could explain 
the failure of TNF inhibitors in treatment refractory patients with IIMs 187. 
 
2.3.9 Role of skeletal muscle in immune regulation 
Muscle tissue is the site for various immunological reactions, which could partly be due 
to role of immune system in muscle repair. However, other functions could also be 
possible.  Muscle fibers and cultured muscle cells not only express immunological 
molecules such as HLA (human leukocyte antigen) class I and class II, cytokine and 
chemokine receptors, co-stimulatory molecules, but also are potent secretor of various 
cytokines, chemokines and MMPs (matrix metalloproteinases). Muscle cells are 
described to be facultative antigen presenting cells under certain conditions (for 
example inflammation). However, the expression of various immune molecules and 
functions could vary between healthy and disease state. Muscle cells are also reported 
to express the immuno-protective molecules HLA-G and B7-H1, which can help to 
control excessive inflammation in muscle tissue 188. Looking at prominent 
immunological and cytokine secretion capabilities, muscle compartment is likely to 
play an active role in immune system homeostasis rather than being a passive target of 
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it.  Evidences from anti-inflammatory effects of exercise strongly suggest such 
mechanisms 189-191.  Therefore, muscle-immune interaction appears to be two ways 
regulated process, where both systems could play role in homeostasis of each other. 
Dysregulation in such interaction could manifest in various pathologies, however such 
mechanisms are not substantially understood so far.   
 
2.3.10 Muscle cells in culture: Myoblasts and myotubes 
From the fresh muscle biopsies specimens (both human and rodents), satellite cells can 
be extracted and expanded into myoblasts in vitro 192. Myoblasts are muscle precursor 
cells, which by fusion, give rise to muscle fibers in vivo and myotubes in vitro 193. In 
culture, myoblasts can be identified by muscle cells specific protein such as desmin and 
also by surface expression of neural-cell adhesion molecule (NCAM, also known as 
CD56). Desmin is an essential muscle cytoskeletal protein and one of the early markers 
for muscle lineage. NCAM is expressed on various immune cells also such as NK cells 
and T cells.  Nevertheless, NCAM can serve as myoblast specific extracellular marker 
among the cells, which are grown from muscle biopsy sample and may contain non-
myogenic cells such as fibroblasts. When cultured myoblasts reaches high confluency 
(80%), myotubes can be generated by fusion of myoblasts by adding fusion-supporting 
medium (such as low serum medium). 194 195 
 
 
Figure 6: Expression of myosin in a cultured human myotube.  
A multinucleated cultured myotube displaying the expression of both slow (green) and fast 
(red) myosin heavy chain proteins. The myotube was obtained by the fusion of human 
myoblasts. Expression of myosin heavy chain is very low or none in single nucleated 
myoblasts.  DAPI (Blue). 
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In contrast to mononucleated myoblasts, myotubes are multinucleated post-mitotic 
syncytial cells similar to skeletal myofibers in vivo. Myotubes express many skeletal 
muscle specific structural, functional and transcriptional proteins that are seen in 
skeletal myofibers in vivo, therefore resemble more closely to skeletal myofibers than 
myoblasts 196-198. Myotubes can be identified by the expression of myosin heavy chain 
(MyHC), an abundantly expressed structural and functional protein in culture  (Figure 
6).  
Both, myotubes and myoblast are described to possess immunological capabilities. 
Although, myoblasts have widely been used as an in vitro system to investigate the 
immunobiological properties of skeletal muscle cells, their usefulness is limited due to 
different properties than myofibers in vivo. For example, antigenic epitopes expressed 
by myoblasts are not seen on muscle fiber. Myoblasts also behave differently to various 
stimuli such as cytokines than myofibers. 188 Therefore, myotubes can serve as better 
system to understand muscle immune interaction.  
The mechanisms of cell death in cultured muscle cells can also depend on their 
differentiation stage, whether they are in form of myoblasts and myotubes. Like in vivo 
myofibers, cultured myotubes are relatively resistant to apoptosis compared to 
myoblasts, which could be due to their multinucleated nature, and up-regulation of anti-
apoptotic molecules such as FLIC (Fas-associated death domain-like IL-1- converting 
enzyme) and anti-caspase mechanisms 129-132,199,200. Some of the classical apoptotic 
features may be absent in cultured myotubes due to apoptosis resistant properties, while 
necrosis can be observed upon extended exposure of cytotoxic agents 199,201. Although, 
allogenic and in vitro expanded T cell clone mediated  cultured myotube and myoblast 
death were shown in in vitro settings, such T cell cytotoxicity are shown using 
Chromium release assays indicating overall lysis (membrane damage) of muscle cells, 
where in depth mechanisms of muscle death were not described 202,203. 
 24 
2.4  FOXP3+ REGULATORY T CELLS  
FOXP3+ regulatory T (Treg) cells are naturally occurring regulatory T cells in the 
immune system, which maintains dominant self-tolerance and immune homeostasis 204. 
The dysfunction/deletion of such cells leads to impaired immune regulation in both 
human and mice, causing severe autoimmune diseases, immunopathology and allergy. 
For example, the loss of function mutation in FOXP3 leads to IPEX 
(polyendocrinopathy enteropathy X-linked syndrome) in human and Scurfy phenotype 
(fatal lymphoproliferative disease, causing death at around 4 weeks of age) in mice. 
Among FOXP3+ T cells, most cells are CD4+ and among them CD25high cells 
(CD4+FOXP3+CD25high T cells) can suppress activation, proliferation, effector 
functions and antigen presentation functions of wide range of immune cells such as 
CD4+ T cells, CD8+ T cells, B cells, Natural Killer (NK) cells and dendritic cells 205. In 
contrast to some T cell subsets, which may acquire regulatory function, natural 
occurring CD4+FOXP3+ Treg cells are developmentally determined in thymus to 
become a specialized T cell subset to exert suppressive functions. Recent studies have 
shown that human CD4+FOXP3+ T cells are not a homogenous population in terms of 
their phenotype, gene expression and mechanisms of suppression. Therefore, molecular 
features, phenotype and functions of Treg cell subsets, is an intense field of research 
presently. 204 Unless stated otherwise, Treg cells in this thesis refer to FOXP3+ 
regulatory T cells.  
2.4.1 Role of FOXP3+ regulatory T cells in skeletal muscle regeneration 
The role of Treg cells in muscle homeostasis and repair was largely unknown, until a 
recent study by Dalia Burzyn and her colleagues 206. Burzyn et al have demonstrated 
that, in mice models of both acute and chronic muscle injury, a distinct population of 
Foxp3+CD4+ Treg cells play important role in muscle repair and maintenance of self-
tolerance towards muscle compartment. The depletion of Treg cells not only prolongs 
the inflammatory phase but also impairs the repair process. This study suggests that 
Treg cells assist the muscle repair process by (i) regulating myeloid cell population by 
promoting a macrophage phenotype switch from proinflammatory (M1) to anti-
inflammatory (M2), (ii) limiting the infiltration of other T subsets (potentially 
proinflammatory) in muscle tissue, and (iii) also directly promoting the regenerative 
potential of satellite cells through secretion of a growth factor called Amphiregulin 
which enhances satellite cell differentiation. Also, as described above in section 1.2.5, 
Treg depletion in mice models of myositis leads to increased muscle damage and 
severe disease 36,37. However, the histopathological and functional aspects of Treg cells 
in patients with inflammatory myopathies, is largely unknown. Whether Treg cells are 
present in adequate numbers to support the muscle repair in IIM muscle tissue? How 
does the conventional immunosuppressive treatment affect Treg cells, particularly in 
muscle tissue? Whether Treg cells in patients with IIMs are able to efficiently suppress 
autoreactive and pathogenic T cells? Whether Treg cells are defective in patients with 
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IIMs or autoreactive T cells are resistant to Treg mediated immunosuppression? Some 
of these questions are addressed in my thesis. 
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2.5 CD28null T CELLS 
 
2.5.1 Definition CD28null T cells 
CD28null T cells are highly differentiated T cells lacking the co-stimulatory molecule 
CD28, in both CD4+ and CD8+ compartment. In the literature, such T cells have been 
studied based on being CD28- T cells (also written as CD28(-) T cells), and also as 
terminally differentiated T cells, effector-memory T cells, Tissue-resident memory T 
cells,  co-stimulation independent T cells, etc. Up to what extent, T cells defined by 
these terms overlap with each other and with CD28null T cells, remains to be clarified. 
We have preferred to use CD28null term over CD28- or other terms mainly because we 
want to emphasize on well-differentiated T cells lacking CD28, rather than T cells 
which may temporarily downregulate surface expression of CD28 during stimulation. 
The differentiation status of CD28null T cells could vary between CD4 and CD8 
compartment. Based on telomere length, it appears that CD28null T cells in CD4 
compartment are terminally differentiated T cells (Figure 7), whereas in CD8 
compartment, CD28null T cells contain both late stage and terminally differentiated T 
cells (Figure 8).  Compared to conventional CD28-expressing T cells, CD28null T 
cells are characterized by the acquired expression of receptors commonly associated 
with natural killer cells, and also by acquired proinflammatory (IFNγ and TNF 
secretion), cytotoxic (contain stored perforin and granzymes even in resting state) and 
apoptosis resistant (upregulation of anti-apoptotic molecules) features. 
Note: Figure 7 and Figure 8 also relate to the section 1.6.3 and section 1.6.5  
 
  
 
Figure 7. Phenotypic dissection 
of human CD4 T cells into 
functionally distinct subsets. 
The expression of markers, 
commonly used to define CD8 T 
cell subsets, enables also the 
distinction between several CD4 
T cell subpopulations, including 
CD4 cytotoxic T cells. (Figure 
and legend reprinted by 
permission from John Wiley and 
Sons. Publication: Appay V et al., 
Cytometry A. 2008 
Nov;73(11):975-83) 
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Figure 8. Phenotypic associations within CD8 T cell subsets in humans and relationship 
with functional attributes. Five distinct subsets of circulating CD8 T cells are defined 
according to the expression of CD27, CD28, CCR7, and CD45RA. Relative telomere length 
and expression of a variety of cell surface receptors and intracellular molecules (related to T 
cell activation, costimulation, regulation, homeostasis, homing potential, and functional 
capacities) are illustrated in these subsets in a “resting” state according to data from the 
literature. The common phenotypic distribution of virus specific CD8 T cells is also depicted, 
after clearance of the virus (Flu) or in latent infection stages (for HCV, EBV, HIV, and CMV). 
(Figure and legend reprinted by permission from John Wiley and Sons. Publication: Appay V et 
al., Cytometry A. 2008 Nov;73(11):975-83) 
Different Pathogens and Distinct T Cell
Response Profiles
Although a com on feature of the immunity against
infections with pathogens is the central role played by CD4
and CD8 T cells, it has become clear that quite distinct profiles
of T cell responses are established for generating memory or
maintaining latency to different pathogens. T lymphocytes
specific for a virus exhibit some degree of heterogeneity;
Figure 1. Phenotypic associations within CD8 T cell subsets in humans and relationship with functional attributes. Five distinct subsets of
circulating CD8 T cells are defined according to the expression of C 27, CD28, CCR7, and CD45RA. Rel tive telomere length and expression
of a variety of cell surface receptors and intracellular molecules (relat d to T cell activation, costimulation, regulation, homeostasis, hom-
ing potential, and functional capacities) are illustrated in these subsets in a ‘‘resting’’ state according to data from the literature. The com-
mon phenotypic distribution of virus specific CD8 T cells is also depicted, after clearance of the virus (Flu) or in latent infection stages (for
HCV, EBV, HIV, and CMV). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
REVIEW ARTICLE
Cytometry Part A ! 73A: 975"983, 2008 977
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2.5.2 Aging and CD28 co-receptor on T cells 
It is evident that there is a decline in effectiveness of the immune system with age, 
particularly in later decades of the human lifespan 207. The decrease in the competency 
of adaptive immune system is mostly assigned to decrease in thymic and bone marrow 
output of lymphocytes as well as the expansion of memory lymphocytes 208. Due to 
such effects, the resulting T cell repertoire becomes less diverse and displays an altered 
phenotype. Among various factors, which comprise the phenotypic shift in the T cell 
system with age, accumulation of CD28null (CD28-) T cells is one of most profound 
and consistent phenomenon. 209,210  
 
 
 
 
 
The gradual decline of CD28 co-receptor expression is seen in both CD4+ and CD8+ T 
cell subsets with age 207,211 (Figure-9). However, this decline is much rapid in CD8+ T 
cell population with 50-60% lacking the expression of CD28 in peripheral blood at the 
age of 80 years and above. In comparison, CD28 decline on CD4+ T cells is less, with 
only 10-15% of T cells turn negative for CD28 until the age of 80 years 211.   
Interestingly, the age related decline in CD28 expression is seen in both human and 
nonhuman primates but not in mice 212.  Whether the reason for this distinction lies in 
the prolonged interactions of the immune system with microorganism during the longer 
life span of primates and humans, or this is an inherent phenomenon of their immune 
system, remains to be explored.  
 
Figure-9 Age-associated 
accumulation of CD28− T cells. A 
schematic presentation of the 
accumulation of CD28− T cells with 
age for both CD4 and CD8 T cells. 
The ordinate indicates the frequency 
of CD28− CD4 or CD28− CD8 T 
cells. CD28− CD8 T cells show a 
much more dramatic increase in 
frequency with age compared with 
CD28− CD4 T cells. 
(Figure and legend reprinted by 
permission from Elsevier. 
Publication: Weng et al, Trends in 
Immunology, Volume 30, Issue 7, 
2009, 306 - 312) 
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2.5.3 Co-stimulatory receptors on CD28null T cells  
There are mainly five members among CD28 receptor family i.e. CD28, CTLA-4 
(CD152), inducible co-stimulator (ICOS), program death-1 (PD-1) and B- and T-
lymphocyte attenuator (BTLA) 213. Surface expression of CTLA-4, ICOS and BTLA is 
usually not detected/reported on CD28null T cells in resting state, however, upon 
activation CD28null T cells are reported to express high levels of CTLA-4 on their 
surface 214,215.  Expression of PD-1 is also reported in CD28null T cells (Figure 8). PD-
1 and CTLA-4 are generally considered inhibitory receptors linked to T cell exhaustion 
216-218, however the expression of these receptors alone does not indicate that a T cell is 
exhausted, and despite the expression of these receptors, human T cells are reported to 
exhibit functional activity 219,220.  CD28null T cells are also negative for the co-
stimulatory molecule CD27 221. Besides CD28 family receptors, NK receptors can also 
function as co-stimulatory molecules in CD28null T cells, which is summarized in 
section 1.6.5.1. 
 
2.5.4 Origins of CD28null T cells  
The restricted T cell receptor repertoire and shortened telomeres in CD28null T cells 
indicate that these cells are originated from repeated division of CD28+ T cells 222-225. 
Repeated division occurs mostly due to antigenic stimulation of TCR, however other 
mechanisms can also be in place such as cytokine-mediated homeostatic proliferation. 
IL-7 and IL-15, which are important for homeostatic maintenance of CD8+ T cells in 
the absence of antigenic stimulation, accelerate the loss of CD28 on the surface 226,227.  
During TCR stimulation, the presence of type-I interferons (IFNα and IFNβ) is also 
known to accelerate the loss of CD28 via telomere erosion 226,228,229. These findings 
suggest that CD28 loss occur in chronic stimulatory and proinflammatory environment, 
which may lead to generation of terminally differentiated CD28null T cells.  
During normal antigenic stimulation, surface expression of CD28 on T cells decreases 
but is rapidly restored to the same level as before. Therefore, CD28 down-regulation is 
interpreted as negative feedback mechanism to prevent excessive T cell stimulation 230. 
However, during continuous T cell stimulation and turnover, CD28 expression is 
reduced and lost eventually.  Initially, CD28 loss can be restored by IL-12 231, however, 
at later stages, CD28 loss is irreversible, suggesting transcriptional silencing of CD28 
expression in CD28null T cells. Indeed, studies point towards defects in transcriptional 
activation of CD28 in CD28null T cells, due to lack of the protein complexes required 
for CD28 transcription initiation 232-234. Such protein complexes are rapidly lost in 
CD8+ T cells upon proliferation but are rather persistent in CD4+ T cells explaining the 
relative resistance of CD4+ T cells regarding CD28 loss 224. The factors known to 
accelerate the loss of CD28 or the factors that can restore CD28 expression, both 
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appears to act on transcriptional assembly level. However, how the transient repression 
is permanently imprinted, is not known. 
 
2.5.5 Molecular and functional features of CD28null T cells  
Although, CD28 is critically important for naive T cell activation, proliferation and 
survival 213,235, the systematic loss of CD28 on T cells is associated with additional 
features. CD28null T cells acquire expression of additional receptors and functions, and 
despite the loss of CD28 on surface, have enhanced cytotoxicity and enhanced 
activation potential, although antigen-induced proliferation response appears to be 
impaired 236. CD28null T cells also display reduced T cell receptor diversity, a sign of 
repeated antigenic stimulation and clonal expansion 237,238.  
CD28null T cells are heterogeneous, and contain different subsets based on the 
expression of CD45RA, CD27 and other markers 221,239,240. Also, the differentiation 
path for CD4+CD28null and CD8+CD28null T cells appears to vary. Molecular and 
functional features of CD28null T cells are not fully understood, and also, there are 
consensus issues regarding definitions of various T cell subsets. Nevertheless, the 
current understanding of T cell subsets, in the context of surface expression of CD28 is 
summarized in Figure-7 for CD4+ T cells subsets, and in Figure-8 for CD8+ T cell 
subsets 239.   
Gene expression analysis studies showed that the expression of a small set of genes 
alters between CD28null and CD28+ T cells 241-243.  Interestingly, the molecular and 
functional features are shared greatly between the CD28null T cells of CD4 and CD8 
compartment 244. In general, there are four major features, which vary in CD28null T 
cells compared to CD28+ T cells. The altered expression of CD28 receptor family 
member is one feature, already described above in section 1.6.3. Other features are 
described below: 
2.5.5.1 Natural Killer cell related receptors  
The acquired expression of various receptors, which are commonly expressed on NK 
cells, is another feature of CD28null T cells. These receptors include CD57, CD244 
(2B4), DNAM-1 (CD226), CRACC, NKG2A, NKG2C (CD94/KLRD1), NKG2D, 
NCR1 (CD355), KIR2DL2, KIR3DL2, KIR2DS2, KLRK1, KLRF1 etc. 245-249. 
Expression of various NK receptors indicates that CD28null T cells are capable of NK 
cell like functions such as cytotoxic killing. Several studies indicate that the final 
outcome of CD28null T cell cytotoxicity could be regulated by stimulatory and 
inhibitory KIRs (killer-cell immunoglobulin like receptors) on CD28null T cells 
245,246,249-252. The activating NK receptors can serve as co-stimulatory receptors on 
CD28null T cells and could lower the threshold for antigen-specific stimulation. 
Indeed, a study in our group demonstrate that pair-wise ligation of CD244 with 
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DNAM-1 and/or NKG2D lead to increased magnitude of activation and effector 
functions of primary CD4+CD28null T cells from rheumatoid arthritis patients 245.   
2.5.5.2 Chemokines, cytokines, and adhesion receptors 
The expression of receptors involved in homing, adhesion and cytokine binding on 
CD28null T cells appears to vary depending on their tissue location, disease condition, 
and is not adequately understood. Nevertheless, the prominent upregulation of 
CX3CR1 (Fractalkine receptor) and CD11b, as well as down-regulation of CCR7 is 
seen on CD28null T cells in both CD8+ and CD4+ compartment 239,253-255. Fractalkine 
is a chemokine when secreted, as well as an adhesion molecule when membrane bound, 
and facilitates migration of CX3CR1-expressing lymphocytes into the tissue 256. 
Interestingly, fractalkine is shown to be involved in the pathogenesis of various 
diseases such as atherosclerosis, multiple sclerosis, glomerulonephritis and rheumatoid 
arthritis 257-260. The lack of CCR7 expression define that CD28null T cells are not the 
central memory T cells, but could belong to effector memory and/or tissue resident 
memory T cells. Interestingly, CD4+CD28null T cells from synovial fluid express 
enhanced expression CXCR3 and CCR6 compared to peripheral blood in patients with 
rheumatoid arthritis 261.  The CXCR3 expression is a feature of Th1 cells, while CCR6 
is expressed on the Th17 subset. Expression of both CXCR3 and CCR6 defines a Th1 
population, which can secrete both IFNγ and IL-17 262,263.   
CD28null T cells also express high level of LFA-1 (Lymphocyte Function-Associated 
Antigen 1) adhesion molecule 236. LFA-1 interacts with its receptor ICAM-1 
(Intercellular Adhesion Molecule-1) on various cells. Interestingly, LFA-1 on T cells is 
also known to lower the T cell activation threshold, which could predispose these cells 
to become autoreactive 264. Regarding cytokine receptors, CD28null T cells are 
reported to express lower levels of IL-7 receptor 239,265, however, expression pattern of 
other cytokine receptors remain largely unknown. 
 
2.5.5.3 Cytokines and effector molecules  
CD28null T cells are reported to express elevated levels of cytolytic molecules such as 
perforin, granzyme-B, granzyme-A and granzyme-H, even in resting state 266,267. In 
CD8+CD28+ T cells, perforin and granzyme-B levels are very low and increased only 
after activation, whereas granzyme-H levels are low both in resting and activated stage. 
On the contrary, higher expression of both granzyme-B and granzyme-H is a cytolytic 
feature, which is shared by both NK cells and CD28null T cells. In addition, CD28null 
T cells normally express high level of IFNγ, moderate levels of TNF and low levels of 
IL-2 upon activation 239,255. Recently, our group demonstrated that, CD4+CD28null T 
cells from synovial fluid of rheumatoid arthritis patients could secrete both IFNγ and 
moderate levels of IL-17 261.  On the contrary, IL-17 secretion is not seen in 
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CD4+CD28null T cells from peripheral blood 261,268. This suggests that CD28null T 
cells can acquire additional functions such as IL-17 secretion in inflamed tissues. In 
general, CD28null T cells are regarded as Th1 phenotype (profound IFNγ secretion) 
cells with NK cell like cytolytic features. 
As mentioned above, several molecular and functional features are similar between 
CD8+CD28null and CD4+CD28null T cells. The important differences and similarities 
between these subsets known so far are summarized subsequent sections.  
 
2.5.6 CD8+CD28null T cells  
The accumulation of CD8+CD28null T cells with age in otherwise healthy individuals 
partly reflects the cumulative infectious burden during the human lifespan. However, 
frequencies of these cells are further increased in people with chronic viral infections 
e.g. HCMV, HIV and EBV, possibly due to repeated activation and clonal expansion. 
Interestingly, such expanded CD8+ T cells, specific for each of these viruses display 
different status of differentiation (Figure-8) 239,269. HCMV reactive CD8+ memory T 
cells subsets appear to be most differentiated, defined by the lack of expression of both 
CD27 and CD28.   
Phenotypically CD8+CD28null T cells are defined as effector memory population in 
the CD8+ T cell compartment. However, as shown in Figure 8, CD8+CD28null T cells 
are heterogeneous mix of population. It is suggested that, depending on the setting, 
CD8+CD28null T cells can either exert increased effector and proinflammatory 
functions or display signs of exhaustion, loss of cytotoxic ability and suppressive 
functions due to expression of inhibitory receptors 270-272. However, it is possible that 
different subsets within CD8+CD28null T cell may have different functional features, 
which remains to be investigated. Nevertheless, several recent reports described 
CD8+CD28null T cells to be proinflammatory and associated with various 
inflammatory disorders 215,273,274. Terminally differentiated, CD8+CD28null T cells are 
described to be resistant to apoptosis 209,273,275. In addition to their proinflammatory and 
cytotoxic effects, CD8+CD28null T cells seem to have negative impact on immune 
system through several other mechanisms, such as constraining the adaptive immune 
system by oligoclonal expansions, and also by competing for available space and 
resources. Such effects can be reflected in elderly individuals as a form of impairment 
of immune system. Nevertheless, the functional aspects of human CD8+CD28null T 
cells and various subsets within this T cell population remain to be explored.  
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2.5.7 CD4+CD28null T cells  
The presence of CD4+CD28null T cells is rare in most individuals until the old age. 
However, the increased frequency of this subset is seen in individuals with autoimmune 
and chronic inflammatory diseases, such as Wegener's granulomatosis 276, Crohn's 
disease 277, rheumatoid arthritis 247,255,278,279, multiple sclerosis280 and atherosclerosis 281-
284. The unusual age-inappropriate expansion of CD4+CD28null T cells in patients 
suffering from these disorders, indicates premature aging of the immune system. This 
early immunosenescence may reflect chronic immune activation in these patients and, 
several findings indicate that CD4+CD28null T cells are likely to contribute towards 
the pathogenesis of these disorders. Although, presence of CD4+ T cells lacking CD28 
was first reported by the group of Hansen and Martin in late 1980s 285, the function of 
these cells were not characterized until late 1990s.  CD4+CD28null T cells were first 
identified in the context of a rheumatoid arthritis by the group of Weyand and Goronzy 
278.  
Although, somewhat similar to CD8+CD28null T cells, CD4+CD28null T cells are 
described to be more strongly associated with HCMV infections 228,286,287. In contrast to 
CD8+CD28null T cells, CD4+CD28null T cells appear to be less heterogeneous 
(Figure 7), and mostly described to be proinflammatory and cytotoxic 246,288-290. 
Similar to CD8+CD28null T cells, CD4+CD28null T cells are described to be resistant 
to apoptosis in vivo 291,292. Furthermore, it was shown recently that CD4+CD28null T 
cells from the peripheral blood of healthy donors were less susceptible to suppression 
by CD4+CD25high regulatory T cells compared to conventional CD4+CD28+ T cells 
293.  However, the detail mechanisms of action of CD4+CD28null T cells, their 
immunosuppression resistant properties and the role in various inflammatory and 
autoimmune disorders, are not well understood so far. 
The literature is growing, which aim to characterize molecular and functional features 
of CD28null T cell subsets, and whether these cells play pathogenic role in immune-
mediated inflammatory disorders. However, CD28null T cell subsets were not 
investigated in the setting of inflammatory myopathies so far. 
 
 
 
 
 
 
 
 34 
 
  35 
3 AIMS 
Despite several evidences indicating a role for T cells in the pathogenesis of myositis, 
precise phenotype and functionality of these cells are poorly understood. Increased 
frequencies of CD4+CD28null and CD8+CD28null T cells were reported in various 
chronic inflammatory disorders, however, the presence of these cells in patients with 
IIMs, particularly in the inflamed muscle, and whether these cells play any role in 
disease pathogenesis, are not known so far. Resistance against regulatory T cell 
immunosuppression in CD4+CD28null T cells led to speculation, whether these cells 
are also resistant to immunosuppression mediated by glucocorticoids, which is the basis 
of current treatment in IIMs. Moreover, apoptosis resistant properties of both subsets of 
CD28null T cells suggested that these cells could escape the apoptotic effects of 
glucocorticoids and could be linked to treatment infectiveness in patients with myositis. 
However, it is not known, how glucocorticoids based immunosuppressive therapies 
affect CD28null T cells, and also FOXP3+ regulatory T (Treg) cells in muscle tissue of 
patients with IIMs  
The overall aim of the studies performed in this thesis was to characterize T cell subsets 
in the disease pathogenesis of inflammatory myopathies, with the emphasis to address 
above questions. The in depth understanding of disease mechanisms and role of T cell 
subsets in IIM pathogenesis may lead us towards developing novel, specific and more 
effective therapies. 
More specific aims were as follow: 
1. to investigate whether CD28null T cells could be effector cells in patients with 
polymyositis and dermatomyositis, and also if these cells are linked with 
HCMV infection (Paper-I). 
 
2. to investigate whether CD28null T cells could be effector cells in patients with 
sporadic inclusion body myositis, where the role of immune cells in disease 
pathogenesis is controversial (Paper-II). 
 
3. to investigate whether T cells, particularly CD28null T cells from patients with 
IIMs, are cytotoxic  to autologous muscle cells in vitro and if yes, what are the 
mechanisms of cytotoxicity (Paper-III). 
 
4. to investigate the effects of conventional immunosuppressive treatment on Treg 
cells and CD28null T cells in IIM muscle tissue and also if CD28null T cells 
display immunosuppression resistant properties in vitro (Paper-IV). 
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4 METHODS 
Methods are described in details in the papers attached. In brief, studies included in this 
thesis investigate T cells from peripheral blood and muscle tissue of patients with IIMs 
and healthy individuals. Peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll separation, from which T cell subsets were obtained using flow cytometry. Flow 
cytometry based methods were widely used for molecular and functional evaluation of 
circulating T cell subsets in all studies included in this thesis. Cytokine secretions in 
culture supernatants (paper-I and paper-III) were measured by a multiplexed method 
known as BD™ Cytometric Bead Array (CBA) (BD Biosciences). HCMV specific 
serum IgG and IgM were measured using ELISA and T cell proliferation was measured 
using thymidin incorporation assay (paper-I). 
Muscle biopsies specimens were mostly obtained from the vastus lateralis or tibialis 
anterior muscle by a “semi-open” technique under local anesthesia 294,295. Evaluation of 
T cells in muscle tissue was done using immunohistochemistry and 
immunofluorescence techniques. Quantitative assessment of T cell subsets in muscle 
tissue was done using computer assistant image analysis softwares.  
For T cell-muscle cell co-culture studies in Paper-III, satellite cells were obtained from 
fresh muscle biopsies and expanded into myoblasts, and further differentiated into 
myotubes. T cell mediated muscle cell death was evaluated using flow cytometry based 
method and calcein release assay. Evaluation of recombinant cytokine induced muscle 
cell death and HLA upregulation was done using flow cytometry. The visualization of 
perforin polarization in T cells towards autologous myotubes, was done using 
immunofluorescence staining followed by confocal microscopy.  
Patient's global disease activity was measured using Visual Analogue Scale (VAS) 
score in myositis (Paper-I). For clinical-evaluation in paper-IV, muscle performance 
was measured by the disease-specific Functional Index (FI) of myositis 296, and post-
treatment 5-years follow up of disease activity was done by "Myositis Intention To 
Treat Activity Index"(MITAX) 297. To measure limitations in daily activities at 5-year 
follow-up, the Health Assessment Questionnaire (HAQ) disability Index was employed 
298.  Serum levels of creatine-kinase (s-CK) were measured doing routine analyses at 
the Department of Clinical Chemistry at Karolinska University Hospital. 
For most of the graphing and statistical analysis, the software program GraphPad Prism 
was used.  In paper-I, the software program STATISTICA 7.0 was used for linear 
multivariate regression analyses, JMP for Kruskal-Wallis nonparametric ANOVA and 
Mann-Whitney analyses. All studies included in this thesis were approved by the local 
Ethics Committee of the Karolinska University Hospital, and both patients and healthy 
subjects gave informed consent. 
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5 RESULTS AND DISCUSSION 
This thesis includes four papers. In this section, major findings from all four papers are 
summarized together with additional unpublished data (related to paper-I) and 
discussed in the context of current literature.  
 
5.1 CD28NULL T CELLS IN PATIENTS WITH POLYMYOSITIS AND 
DERMATOMYOSITIS (PAPER-I) 
In this study, phenotypic characterization of T cell subsets was done in both muscle 
tissue and peripheral blood of patients with PM and DM. Furthermore, T cell subsets 
were investigated in the context of human cytomegalovirus (HCMV) infections and 
clinical relevance.   
5.1.1 Evaluation of frequency, phenotypic and functional potential of 
CD28null T cells 
Using a cohort of 42 PM and 24 DM patients, we have found that CD28null T cells 
were present in higher frequencies in peripheral blood of patients with PM and DM 
compared to age and gender matched healthy individuals. Circulating CD28null T cells 
also displayed proinflammatory and cytotoxic features.  To investigate CD28null T 
cells in the muscle tissue, we needed to identify a positive surrogate marker. With the 
identification of positive surrogate marker, we can avoid inclusion of T cells, which 
temporarily downregulate CD28 upon activation. Towards this, we found that majority 
of circulating CD28null T cells, 89% (median) of CD4+CD28null and 98% of 
CD8+CD28null T cells express the NK cell receptor CD244 on their surface. In order 
to investigate CD244 expression on T cells in myositis muscle tissue, we used triple 
color immunofluorescence staining, and found that in muscle tissue too, CD244 was 
mainly expressed by cells coexpressing CD3. This indicates that the majority of the 
CD244-expressing cells are T cells, and not NK cells in myositis muscle tissue. Using 
CD244 as a surrogate marker in triple color immunofluorescence stanings, we 
demonstrated that muscle-infiltrating T cells are predominantly CD8+CD28null 
(CD3+CD4-CD244+, median 79%) and CD4+CD28null (CD3+CD4+CD244+, median 
59%) T cells in patients with PM and DM. While comparing the relative abundance, 
CD4+CD28null T cells displayed significantly higher frequency in muscle tissue 
compared to peripheral blood of same individuals (median 59% versus 6% p < 0.0001), 
while the frequency of CD8+CD28null T cells were high in both muscle and peripheral 
blood. Despite the confirmation that the expression of CD244 was mainly on T cells in 
muscle, there are limitations with the use of CD244 as a surrogate marker, because 
CD244 can be also expressed by a small proportion of CD8+CD28+ T cells. To further 
substantiate presence of CD28null T cells in the muscle, we used double 
immunofluorescence stainings of seven infiltrates in muscle tissue, with CD4 and 
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CD28 or CD8 and CD28 and confirmed the lack of CD28 on approximately 64% of the 
CD4 T cells and 60% in CD8+ T cell subsets (Figure 10).  However, there could be 
limitations with this method too, because a report demonstrates that muscle fibers and 
myoblasts can also express costimulatory molecules in inflammatory cytokine milieu, 
which are known to be expressed on T cells such as CD28 and CTLA-4 299. In our 
study as well, CD28 staining in muscle did not display a characteristic circular 
membrane staining like CD4 or CD8, but was varied from rather weak to focal 
granular. Such pattern of expression is suggestive of sarcolemma and sarcoplasmic 
reticulum/T tubule pattern indicating the expression on muscle fibers themselves, and 
was similar with the CD28 expression pattern in myositis muscle tissue shown by 
Nagaraju et al. Therefore, the identification of CD28null T cells with the lack of CD28 
staining approach in muscle tissue could lead to underestimation of the CD28null T cell 
number assessment.   
 
Figure 10: Polymyositis muscle tissue displaying the expression of CD4, CD8 and CD28. 
Representative staining of skeletal muscle section of polymyositis patient displaying CD4 
(green) or CD8 (green) and CD28 (red) (CD28). The staining shows the absence of CD28 on 
many of the CD4+ and CD8+ cell in muscle tissue. Also, it shows an unusual staining of CD28 
in muscle tissue from weak to focal granular, suggestive of the expression on muscle fibers 
rather than T cells. 
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5.1.2 Clinical relevance  
Subsequently, various subpopulations of T cells were correlated with clinical 
parameters of the patients. Presence of CD28null T cells at the disease onset in muscle 
tissue and correlation of muscle infiltrating CD8+ T cells (of which majority were 
CD28null T cells) with disease activity in patients, support the clinical relevance of 
these cells. The increase in circulating CD8+CD28null T cell frequency with age 
indicates a role of age dependent immunosenescence mechanisms in IIM pathogenesis. 
The decrease in frequency of circulating CD28null T cells subsets with disease duration 
could be due to the effect of ongoing treatment in these patients, or it is also possible 
that these cells are consumed while causing inflammatory damage during disease 
duration. However, these speculations need be confirmed by future studies.  
5.1.3 Link with Human Cytomegalovirus 
The increased frequency of CD28null T cells in both CD8+ and CD4+ compartment 
have been linked with chronic viral infections, particularly HCMV. Similarly, we also 
found that circulating CD28null T cells are predominantly found in patients 
seropositive for HCMV. To further investigate the association between CD28null T 
cells and HCMV infection, we investigated whether CD28null T cells display any 
specific reactivity towards HCMV T cell antigens such as pp65 and IE, using IFNγ 
production as read-out.  We found that both CD8+CD28null and CD4+CD28null T 
cells from HCMV seropositive patients responded to the pp65 antigen by producing 
high IFNγ whereas CD28null T cells from HCMV seronegative patients did not display 
such levels of response. On the contrary, CD28+ T cell subsets from both HCMV 
seropositive and seronegative patients showed lack of response towards HCMV 
antigens. Moreover, the minor response in CD28null compartment towards influenza 
strengthens the association of CD28null T cells particularly with chronic viral 
infections.  
In summary, this study identifies CD28null T cells as the dominating effector T cell 
subsets in muscle tissue of patients with PM and DM. It further explores the molecular 
and functional features of CD28null T cell subsets, their clinical relevance and possible 
link with HCMV infections.   
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5.2 CD28NULL T CELLS IN PATIENTS WITH SPORADIC INCLUSION 
BODY MYOSITIS (PAPER-II) 
Frequency, clonal expansions and functional evaluation  
Although, cytotoxic CD8+ T cells invading MHC class I expressing muscle fiber have 
been implicated in sIBM pathogenesis 23,24,300,301, the absence of beneficial effects of 
conventional immunosuppressive therapies and the lack of signs of the systemic 
inflammation has questioned the role of immune system and T cells in sIBM 
pathogenesis 302,303. Since CD28null T cells are described as long-lived and resistant to 
apoptosis in vivo 273,291,292, it was compelling to investigate presence and functionality 
of CD28null T cells in the peripheral blood and muscle tissue of patients with sIBM. 
In a cohort of 27 patients with sIBM, we found strikingly higher frequency of 
circulating CD28null T cells in both CD8+ and CD4+ compartment compared to the 
healthy controls. In muscle compartment too, CD28null T cells dominated the T cell 
infiltrate (median 72%, range 42.5-96%). Circulating CD8+CD28null and 
CD4+CD28null T cell subsets upon stimulation, not only displayed higher IFNγ 
secretion potential, but also were capable of degranulating more compared to CD28+ T 
cell subsets.  
Clonal expansions in the CD8+ T cell populations of sIBM patients, have been reported 
previously 33,304, a feature that is shared with CD28null T cells 292. Using TCR-Vβ 
repertoire analysis of circulating T cells, we also observed striking clonal T cell 
expansions in both CD4+ and CD8+ compartment in patients with sIBM. Importantly, 
we demonstrated that the clonal expansion observed in the total CD8+ and CD4+ T cell 
populations of sIBM were predominantly due to clonally expanded CD28null T cells. 
Such clonal expansions in CD28null T cells indicate repeated antigenic stimulation 
scenario. Furthermore, we demonstrated that clonally expanded TCR-Vβ which were 
dominant in circulation, were also present in the inflamed muscle of the respective 
patients, indicating shared antigen-specificity of CD28null T cells between inflamed 
muscle tissue and peripheral blood.  
Persistent antigen-specific activation and clonal expansion is indicative of shifting the 
balance towards immunosenescence, which may lead to impaired functions of immune 
cells. Investigating, whether clonally expanded CD28null T cells still retain 
proinflammatory functions, we have shown that CD28null T cells with dominant TCR-
Vβ are equally capable of IFNγ secretion and degranulating as CD28null T cells with 
non-dominant TCR-Vβ. This indicates that these cells were not functionally senescent 
but potent to exert proinflammatory and cytotoxic functions.  
Overall, finding in this study suggests, that clonally expanded T cells in muscle and 
peripheral blood of patients with sIBM belong to CD28null T cells. These cells 
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dominate T cell infiltrate in muscle tissue and display proinflammatory and cytotoxic 
properties.  
 
5.3 MYOTOXIC POTENTIAL OF CD28NULL T CELLS AND THE 
MECHANISMS INVOLVED (PAPER-III) 
After observing the high frequencies of CD28null T cells both in muscle tissue and 
peripheral blood of patients with IIMs, along with the proinflammatory and cytotoxic 
features, we were interested to investigate, whether CD28null T cells from patients with 
IIMs directly exert cytotoxic functions towards autologous muscle cells, and if they do, 
what are the mechanisms involved. In order to explore myotoxic functions of T cell 
subsets, we employed a fully autologous in vitro human T cell-muscle cell co-culture 
system, in which the cytotoxic functions of T cell subsets alone towards muscle cells 
can be explored. To study autologous T cell-muscle cell interactions, we obtained 
muscle biopsy and peripheral blood samples from 6 patients with PM. Muscle stem 
cells were extracted from muscle biopsies and differentiated into myotubes, while T 
cell subsets were obtained from peripheral blood. For co-cultures studies, differentiated 
cultures with myotubes were preferred because myotube phenotype is more close to in 
vivo muscle fibers such as expression of contractile and structural muscle protein e.g. 
myosin. Autologous muscle cells were co-cultured with either un-stimulated or 
stimulated T cell subsets and T cell cytotoxicity towards muscle cells were confirmed 
by two different methods.  
Using above setup, we demonstrated, that CD28null T cells are directly cytotoxic to 
autologous muscle cells. Moreover, we found that CD28null T cell subsets were 
spontaneously cytotoxic to autologous muscle cells in culture without any 
stimulation/reactivation. This indicates that a significant proportion of CD28null T cells 
is already primed towards muscle compartment in these patients. However, un-
stimulated CD28null T cells did not display a dose response (data not shown) or 
significantly higher cytotoxicity than CD28+ counterparts in co-cultures, indicating the 
possible requirement of additional factors/immune cells for maximum cytotoxicity 
potential, which could be absent in our in vitro settings. Nevertheless, upon co-culture 
in stimulatory environment, both CD28null T cell subsets significantly induced more 
cell death in autologous muscle cells than CD28+ counterparts.  
We have also shown here that myotubes were more prone to cell death induced by 
CD28null T cells compared to myoblast. Myotubes in cultures are considered to have 
more resistance to chemically induced apoptosis and/or cell-death compared to 
myoblasts 130,131,201. On the contrary, CD28null T cell subsets were able to induce more 
cell-death in autologous myotubes compared to myoblasts. This suggests that a 
majority of CD28null T cells could be primed towards structural or functional proteins, 
which are specifically expressed in myotubes compared to myoblasts, such as myosin. 
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However, muscle specific autoantigen reactive to CD28null T cells remain to be 
identified.  
Exploring the CD28null T cell mediated mechanism of muscle cell death, we have 
shown that not only CD8+CD28null but also CD4+CD28null T cells displayed perforin 
polarization towards muscle cells and secreted higher levels of granzyme-B and IFNγ 
in co-culture than CD28+ subsets. This determines that both CD8+CD28null and 
CD4+CD28null T cells can directly kill muscle cell by perforin-dependent 
mechanisms. To decipher the perforin and cytokine mediated cytotoxic/myotoxic 
effects, we performed various blocking experiments. By blocking perforin, the 
myotoxicity was reduced by a median of 52% with CD4+CD28null T cells and by 56% 
in cultures with CD8+CD28null T-cells indicating that perforin-mediated pathway is 
one of the major mechanisms of CD28null T cell cytotoxicity towards muscle cells. 
Nevertheless, blockade of IFNγ and TNF in co-cultures also reduced the level of dead 
muscle cells by 46% (CD4+CD28null) and 53% (CD8+CD28null). This indicated the 
essential role proinflammatory cytokines also in the CD28null T cell mediated 
myotoxicity.  However, TNF or IFNγ did not induce death of muscle cells in the 
absence of T cells, suggesting that these cytokines can have other effects in the context 
of T cell mediated cytotoxicity such as priming of muscle cells by HLA upregulation. 
Indeed, we found that cytokines, particularly IFNγ did upregulate both HLA class I and 
class II on muscle cells. Therefore, the reduced myotoxicity upon blocking of IFNγ and 
TNF is likely attributed to interference with HLA upregulation, as HLA blockade 
resulted in a comparable reduction in myotoxicity, 61% for CD4+CD28null and 55% 
for CD8+CD28null T cell co-cultures. 
Overall, the study demonstrates that CD28null T cells are cytotoxic to autologous 
muscle cell in polymyositis patients. The myotoxic effects of CD28null T cells appear 
to be predominantly exerted via perforin-granzyme pathway and regulated by IFNγ-
induced HLA expression by muscle cells. 
 
 
5.4 EFFECTS OF IMMUNOSUPPRESSION ON T CELL SUBSETS IN IIM 
(PAPER IV) 
5.4.1  Effects of conventional immunosuppressive treatment on 
CD28null and regulatory T cell subsets in muscle tissue of PM 
and DM 
Treatment of PM and DM is based on the use of glucocorticoids in high doses over an 
extended period of time, but treatment outcome is unpredictable.1 In some patients, the 
inflammatory infiltrate including T cells persists in muscle-tissue despite aggressive 
treatment and is associated with remaining muscle weakness.83-85 Although, we have 
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identified CD28null T cells as dominant T cell subset in muscle tissue of myositis 
patients, FOXP3+ Tregs have also been reported in myositis muscle-tissue in close 
proximity to effector cells.305 Therefore, it was intriguing to investigate whether 
persistent T cells in affected muscle could be denoted to FOXP3+ regulatory T (Treg) 
cells or proinflammatory CD28null T cell subsets.  
Looking at the relative frequency, CD28null T cells dominated the T cell infiltrates 
over Treg cells in inflamed myositis muscle-tissue. Overall numbers and freqeuncies of 
FOXP3+ cells were very low in our cohort and were similar with findings in the 
Waschbisch et al report 306. However, this is the first study, which investigates the 
frequencies FOXP3+ Treg cells in relation to the CD28null T cells and how their 
relative proportion is affected in myositis muscle-tissue by immunosuppressive 
treatment. Interestingly, after treatment, CD28null T cells were found to be unchanged 
while the number of Treg cells had declined, leading to a relative increase in the 
proportion of CD28null T cells over Treg cells. The CD28null T cells have been 
reported to be long lived and apoptosis resistant in vivo, 273,291,292 which has been linked 
with the increase in anti-apoptotic protein Bcl-2 291. Furthermore, CD28null T cells also 
display replicative senescent properties,307-309 and we have also demonstrated this in the 
setting of myositis 310.Therefore, it is possible that CD28nulls T cells can escape the 
apoptotic effects of high doses of glucocorticoids as well as anti-proliferative effects of 
concomitant immunosuppressive drugs, leading to their persistence in muscle-tissue.  
 
5.4.2 In vitro immunosuppressive effects of glucocorticoids and 
regulatory T cells on CD28null T cell subsets 
How about the immunosuppressive effects of glucocorticoids? Whether glucocorticoids 
can suppress CD28null T cells efficiently? A report has shown that CD28null T cell 
proliferation and function could only partly be suppressed by Treg cells in healthy-
donors 293. Therefore, we further investigated the immunosuppressive effects of 
glucocorticoids and Treg cells on CD28null T cell subsets using in vitro 
immunosuppression assays. We have evaluated the suppression effects on the T cell 
activation (using early T cell activation marker CD69) rather than on T cell 
proliferation, due to replicative senescent properties of CD28null T cells (as described 
above). We validated that CD69 is unregulated on both CD4+CD28null and 
CD8+CD28null T cells upon activation. Interestingly, we found that both 
glucocorticoids and Treg are less capable of suppressing of CD4+CD28null T cells 
compared to their CD28+ counterparts.  
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5.4.3 Clinical relevance of persistent CD28null T cells in myositis 
muscle tissue 
Whether persistence of such proinflammatory and immunosuppression resistant 
CD28null T cells is related to the post-treatment disease outcomes in IIMs?  Indeed, we 
further demonstrated that the higher number of CD28null T-cells in the post-treatment 
muscle biopsies correlated with a poor clinical response both in short-term (Functional 
Index) and long-term (disease activity measurement by MITAX) clinical perspectives. 
In summary, in this study, we demonstrated that current treatment regime based on high 
doses of glucocorticoids in combination with conventional immunosuppressive agents 
is insufficient to eliminate CD28null T cells in inflamed muscle of patients with PM 
and DM. CD28null T cells were found to be relatively resistant to both glucocorticoid 
and Treg mediated immunosuppression and were also linked with poor clinical 
outcome from conventional immunosuppressive treatments. These findings could 
provide explanations concerning the inefficacy of current treatment approach, if not for 
all, at least for a subgroup of myositis patients. Furthermore, it suggests that a specific 
targeting of proinflammatory T cells could form the basis of better future therapies in 
patients who are resistant to current immunosuppressive treatments.  
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6 THESIS SUMMARY AND CUMULATIVE 
DISCUSSION 
Findings in the paper-I and paper-II, establish a new angle to look at the T cell 
phenotype in the pathogenesis of myositis. According to classical dogma, mainly CD8+ 
T cell were considered to be involved in PM and sIBM pathogenesis, while attack on 
the microvasculature via CD4+ T cell mediated humoral immunity were considered to 
play major role in DM pathogenesis. The demonstration of significantly increased 
presence of CD8+CD28null and CD4+CD28null T cells in peripheral blood as well as 
in muscle tissues of PM and DM, defines rather precise phenotype of T cells in these 
compartments, which are potentially pathogenic. The findings in this thesis explains the 
inadequate expression of CD28 in myositis muscle tissue seen by some other 
investigations, although such studies did not put emphasis on CD28null phenotype in 
the muscle tissue 311,312. Moreover, our data could also shed light on instances where 
CD28 expression was completely lacking despite T cell infiltrate in muscle tissue, such 
as in patients with Duchenne muscular dystrophy 311. Furthermore, previously reported 
enhanced expression of CTLA-4 on the T cells in contact with muscle fibers could be 
elucidated by CD28null phenotype because CD28null T cells are described to 
upregulate CLTA-4 upon activation 214,215,311,312.  
The phenotypic characterization of CD28null T cell subsets in peripheral blood as well 
as muscle tissue in paper-I provides the tools to explore CD28null T cells in the 
muscle compartment, which is trickier. The findings in paper-II demonstrate that the 
clonally expanded T cells seen in the muscle tissue and peripheral blood of sIBM are 
CD28null T cells. Furthermore, the functional characterization CD28null T cells in 
both paper-I and paper-II, reveal phenotype of these T cell subtypes, which are 
proinflammatory and cytotoxic, and could possibly play role in disease mechanisms 
and muscle pathogenesis.   
Although, we haven't evaluated clonal expansions in PM and DM so far, the results 
from the paper-II may have implications for other subsets of IIMs, where clonally 
expanded T cells were defined to be auto-aggressive T cells attacking muscle fibers 
34,313. Of note, in synovial tissue of Rheumatoid Arthritis, CD28null T cells are not 
enriched despite high levels in peripheral blood 238. This suggests that CD28null T cell 
phenotype in affected organs is not a general finding in any chronic inflammation, but 
could be more specific for certain diseases or certain organs such as in inflamed 
muscles in myositis. 
The higher presence of CD28null T cell subsets in HCMV seropositive patients and 
their reactivity to HCMV derived antigens suggest a possible role for HCMV and/or 
chronic infections in the pathogenesis of myositis (paper-I). The presence and 
replications of chronic viruses such as HCMV or HIV in muscle tissue is controversial 
10,42,54,70. Nevertheless, it is possible that CD28null T cells migrate to muscle after 
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encountering HCMV at other sites in the body. The co-occurrence of both CD4+ and 
CD8+ CD28null T cells has been suggested to be associated with HCMV-induced 
IFNα production by plasmacytoid DC 226,228,229. Interestingly, plasmacytoid DCs and 
the IFNα-induced protein MxA were frequently found in muscle tissue from patients 
with dermatomyositis and polymyositis 314,315. There are reports describing a link 
between the long-term use of IFNα, particularly for the treatment of chronic hepatitis C 
virus infection and development or exacerbation of numerous autoimmune phenomena 
and spectrum of myopathies 316,317. Also, HCMV specific effector memory CD8+ T 
cells have been also reported to express high levels of CD244 318. Above findings 
indicate direct and/or indirect role of chronic viral infections in inflammatory 
myopathies. 
It is still debated whether T cells have a roll in the pathogenesis of sIBM or it is merely 
a degenerative muscle disease, largely because most patients are refractory to current 
immunosuppressive therapies. We demonstrate the enhance presence of CD28null T 
cells in muscle tissue and peripheral blood of patients with sIBM (Paper-II). CD28null 
T cells are described to be resistant to apoptosis in vivo 273,291,292, therefore it is possible 
that conventional immunosuppressive therapies are not able target these cells, 
particularly in muscle tissue. According to a recent proof-of-principle study involving 
13 patients with sIBM, who underwent one series (0.3 mg/kg/day for 4 days) of 
alemtuzumab (a humanized monoclonal antibody to CD52 that causes depletion or 
severe reduction of circulating mature lymphocytes) infusions, could slow down 
disease progression up to six months, improved strength of some patients, and reduced 
endomysial inflammation in muscle tissue 319. Although, these preliminary results are 
promising towards the targeting of immune cells as sIBM therapies, alemtuzumab is 
associated with lot of adverse effect to due generalized targeting of lymphocytes. 
Therefore, specific targeting of proinflammatory and pathogenic T cell subsets such as 
CD28null T cells should be more appropriate approach towards therapies in sIBM. 
To elucidate the myotoxic potentials of T cell subsets and mechanism involved, we 
established an autologous T cell-muscle cell co-culture approach (paper-III). In vitro 
manipulation such as extended cultivation including cloning of T cells can alter their 
phenotype and functionality, therefore, we choose to use primary T cells from patients 
without in vitro expansion, although, it limited the number T cells, hence the various 
experimental conditions we could test in co-culture studies. The demonstration of 
perforin-granzyme pathway in CD28null T cell myotoxicity, including the role IFNγ 
and TNF, provide better understanding of the role of T cells in muscle pathogenesis.   
Finally, in paper-IV, we provide evidence that, indeed CD28null T cells are persistent 
in the muscle tissue of patients despite aggressive immunosuppressive treatment, and 
associated with poor clinical outcomes. Also, CD4+CD28null were found to be 
resistant to immunosuppression mediated by both glucocorticoids and Treg cells. The 
absence of clear pattern in CD8+CD28null T cells regarding immunosuppression 
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resistance could be due to heterogeneity of this T cell subset, which remains to be 
dissected in future studies.  Interestingly, a recent study in patients with PM and DM 
shows that after high dose IVIG treatment, the frequency of IFNγ producing cells was 
significantly higher in muscle tissue of non-responders compared to responders, with an 
increased IFNγ/IL-17-producing-cell ratio 320. These results further point towards 
CD28null phenotype in the muscle tissue, especially in patients that are resistant to 
immunosuppression. 
Apparently, there are additional limitations in various studies, which could not be 
mentioned above. The major limitations with all the studies, was the limited availability 
of patient samples, both muscle biopsies and peripheral blood due to myositis 
belonging to rare disease category. Due to that, we could only perform restricted set of 
experiments in many instances, for example co-culture studies. Also, low patient 
numbers led to difficulties in finding statistically significant results, which further 
became difficult in case of clinical parameters correlations, due to inadequate 
availability of the clinical data. To curtail such limitations, we have pooled the data 
from different IIMs subtypes in some cases, for example throughout in paper-IV and 
some instances in paper-I. Although, we are aware of subtype differences, the pooling 
of data may provide insight into common pathogenic mechanism in different subtypes. 
Also, it is time to re-evaluate the old dogmas on IIM subtypes and classify patients 
according to molecular and cellular markers, where CD28null T cell subsets could 
serve as proinflammatory T cell markers. Classifications based on molecular and 
cellular makers are proving better in understanding disease mechanisms and deciding 
treatment strategies.    
 
6.1 THE PROPOSED MODEL 
Based on findings in this thesis, and previous understanding of skeletal muscle-immune 
system interaction, following model is proposed summarizing the role of T cell subsets 
in disease mechanisms of inflammatory myopathies (myositis) (Figure 11). 
Figure 11a and 11b describe that both immune system and skeletal muscle play 
important role in the homeostasis of each other. In a healthy person, after skeletal 
muscle injury, cells linked to the immune system including T cells play crucial role in 
the repair and regeneration process. The neutrophils and M1 macrophages 
(proinflammatory) cause further transient inflammatory damage in the muscle tissue. 
This is followed by phenotypic switch in macrophages from M1 to M2 (anti-
inflammatory) at the site of injury. M2 macrophages dampen the inflammation and 
induce/help in satellite cell mediated muscle regeneration and remodeling process. 
FOXP3+ regulatory T (Treg) cells not only induce phenotypic switch in macrophages 
from M1 to M2, but also directly promote regenerative potential of satellite cells via 
secretion of a growth factor called Amphiregulin. In addition, Treg can suppress/limit 
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occasional autoreactive T cells, which could potentially attack muscle fibers.  Towards 
another direction, a healthy skeletal muscle possesses various immunological and 
cytokine secretion capabilities and is known to have anti-inflammatory effects on the 
immune system such as in setting of exercise.  
In young and healthy individuals, T cells are efficient in maintaining homeostasis and 
immune tolerance in skeletal muscle (Figure 11a). During human lifespan, various 
factors promote the accumulation of CD28null T cells such as chronic stimulation (both 
antigenic and cytokine mediated), chronic viral infections, type-I interferon mediated 
telomere erosion. Depending on genetic and environmental factors, this process can be 
rapid in some individuals. T cell repertoire with increased frequencies of CD28null T 
cells display several  
 
 
Figure 11a: Differences in skeletal muscle-immune system interaction in healthy verses 
myositis settings, and effects of T cell repertoire. Green arrow: Inducing/promoting effect, 
Broken lines: Impaired effects. 
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Figure 11b: Role of immune cells in muscle repair and regeneration in a healthy person.  
Green arrow: Inducing/promoting effect, Blue lines with bar: Blocking effect, Broken lines: 
Impaired effects. 
 
 
 
 
Figure 11c: Role of T cell subsets in the pathogenesis of myositis.  
Green arrow: Inducing/promoting effect, Blue lines with bar: Blocking effect, Broken lines: 
Impaired effects. 
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Patients with inflammatory myopathies display accumulation of CD28null T cells in 
both peripheral blood and muscle compartment (Figure 11a). Due to proinflammatory 
and cytotoxic capacity, CD28null T cells can directly induce muscle damage, and can 
maintain perpetual chronic inflammation in muscle tissue (Figure 11c). 
Proinflammatory cytokines from CD28null T cells such IFNγ and TNF can promote 
M1 phenotype macrophages and prevent the phenotype switch to M2. These effects 
would manifest in chronic inflammatory damage and impaired muscle repair, which 
can further lead to chronic stimulation and expansion of CD28null T cells and breakage 
of immune tolerance. Despite massive T cell infiltrates in muscle tissue of myositis, the 
numbers of FOXP3+ Treg cells are few, which imply that processes induced by Treg 
cells may be impaired due to their inadequate number. Furthermore, 
immunosuppression resistant properties of CD4+CD28null T cells could make the 
regulatory effects of Treg cells and glucocorticoids less relevant in setting of myositis. 
The long-term use glucocorticoid can also have catabolic effects on skeletal muscle. 
Overall, the enhanced presence of CD28null T cells and lower number of Treg cells, 
may possibly explain the pathogenesis and treatment ineffectiveness in inflammatory 
myopathies.  
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7 CONCLUSIONS  
The results in this thesis provide improved understanding of the phenotype of 
pathogenic T cells and their role in the disease mechanisms in inflammatory 
myopathies.  The phenotypic characterization of CD28null T cell subsets in all three 
major subtypes of IIMs equips us to explore these cells for the future inflammatory 
myopathies research. Furthermore, their mechanism of action towards muscle cell 
death and role in inefficacy of current therapies provide us with a better understanding 
of disease pathogenesis and a possible direction for efficient future therapies.  In the 
included studies, we show that: 
• CD28null T cell subsets dominate the T cell infiltrate of inflammed muscle, and 
also display increased presence in circulation, in all theree subtypes of IIMs i.e. 
PM, DM and sIBM. 
• CD28null T cell subsets from patients with IIMs display proinflammatory and 
cytotoxic features. 
• HCMV infections are linked with the expansions of CD28null T cells in PM 
and DM. 
• The myotoxic effects of CD28null T cells are mediated predominantly via 
perforin-granzyme pathways and regulated by proinflammatory cytokines such 
as IFNγ and TNF. 
• The inefficacy of conventional therapies in PM and DM are linked to 
persistance of immunosuppression resistant CD28null T cells in the muscle 
tissue. 
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8 FURTURE PERSPECTIVES  
An important future direction is the therapeutic targeting of CD28null T cells in 
myositis, preferably first in relevant animal models. However, the absence of natural 
occurrences of CD28null T cells in mice has limited the CD28null T cells research 
field. Therefore, efforts should be made to develop relevant rodent models of myositis, 
where pathogenic mechanism of CD28null T cells can be studied further in in vivo 
setting.  Also, it would be more appropriate to study CD28null T cells in relevant 
primates cases of natural inflammatory myopathies, such as myositis associated with 
natural infections with retrovirus 51.  
Nevertheless, some progress can be made with existing rodent models, combined with 
the growing knowledge of human CD28null T cells.  A previous study in our group has 
demonstrated that circulating CD4+CD28null T cells from rheumatoid arthritis patients 
display predominantly effector-memory T cell phenotype 255.  Several other studies also 
implicate the role of effector-memory T cell population in pathogenesis of various 
chronic inflammatory disorders, and such effector memory T cells are described to 
express high level of voltage-gated potassium channel, Kv1.3, particularly in activated 
state 280,321-325. More recent studies describe the selective targeting of CD4+CD28null T 
cell population (or CD4+ effector-memory T cells), by targeting Kv1.3 channels, which 
mainly inhibited the effector functions of CD4+CD28null T cells 325-327.  The Kv1.3 
potassium channel has been reported as an important regulator for influx of potassium 
ions critical for exocytosis of cytoplasmic granules, including perforin and IFNγ 
containing granules, on CD4+CD28null T cells 326. The therapeutic potential of Kv1.3 
inhibitors has been evaluated in few rat models of autoimmune disorders such as 
rheumatoid arthritis, type I diabetes mellitus and atherosclerosis, where inhibition of 
Kv1.3 ameliorated the disease and associated pathogenic features 325,327. Interestingly, it 
has been reported that mouse models of autoimmune disease are not suitable for 
evaluating the effects of Kv1.3 inhibitors, because Kv channels doesn't seem to regulate 
the membrane potential of mouse T cells 325,328,329 and the potassium channel 
expression pattern of repeatedly activated mouse T cells are very different from that of 
human T cells 330330. Therefore, I recommend that future studies evaluating the effects 
of Kv1.3 blockers should be performed in rat models of myositis rather then mice 
models of myositis.  
Moreover, the literature is less clear about the expression and blocking effect of Kv1.3 
on CD8+CD28null T cells.  Therefore, before targeting CD28null T cells in patients 
with IIMs by Kv1.3 inhibitors, extensive phenotyping of various T cell subsets, 
including both CD4+CD28null and CD8+CD28null T cells, should be performed with 
respect to the specific expression of such potassium channels in patients. Inhibiting ion 
channels in patients should be carried out with caution, as non-specific binding to other 
ion channels such as on heart muscles or on neurons can have serious side effects. 
Moreover, risk of infections should be evaluated before targeting effector-memory or 
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tissue resident-memory T cells. In this direction, we could benefit from the knowledge 
on antigen specificity of T cells, where specific targeting of autoreactive CD28null T 
cells could help us reducing the risk of infections. Overall, the data in this thesis and 
relevant literature suggest that the selective targeting of CD28null T cells could hold 
the key to future therapies in myositis.
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